DK152482B - Osmotisk drevet organ til reguleret indgift af et aktivt middel til et vandigt, surt vaeskemiljoe - Google Patents
Osmotisk drevet organ til reguleret indgift af et aktivt middel til et vandigt, surt vaeskemiljoe Download PDFInfo
- Publication number
- DK152482B DK152482B DK184681A DK184681A DK152482B DK 152482 B DK152482 B DK 152482B DK 184681 A DK184681 A DK 184681A DK 184681 A DK184681 A DK 184681A DK 152482 B DK152482 B DK 152482B
- Authority
- DK
- Denmark
- Prior art keywords
- active agent
- wall
- water
- compartment
- osmotically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
i
DK 152482 B
Den foreliggende opfindelse angår et osmotisk drevet organ til reguleret indgift af et aktivt middel til et vandigt, surt miljø, hvilket organ består af en med en gennemstrømningsåbning forsynet semipermeabel polymervæg, der omgiver og danner 5 et rum og er permeabel for passage af vand og i det væsentlige impermeabel for passage af et i rummet indeholdt aktivt middel .
Osmotisk drevne organer fremstillet i form af tabletter til at 1Q administrere en medicin til mave- og tarmkanalen kendes fra US-patentskrift nr. 3.845.770 og 3.916.899. Et typisk heri beskrevet drevet organ omfatter en semipermeabel væg, der omgiver et rum, der indeholder et aktivt middel. Væggen er permeabel for en ydre væske og i det væsentlige uigennemtrængelig 15 for det aktive middels passage. Der er en gennemstrømningsåbning gennem væggen til at afgive det aktive middel fra systemet. Systemet frigiver det aktive middel ved hjælp af væske, der kontinuert suges gennem væggen ind i rummet ved en hastighed, der bestemmes af væggens permeabilitet og den osmotiske 20 trykgradient gennem væggen til frembringelse af en opløsning indeholdende et opløseligt aktivt middel, der dispenseres fra systemet i løbet af tiden.· I US-patentskri ft nr. 4.036.228 beskrives et osmotisk drevet organ til at administrere aktive midler, der er vanskelige at 2 5 administrere, især aktive midler, der er praktisk taget uopløselige i vandige væsker. Det drevne organ benyttes ved at fylde organet med et par indbefattende en sur komponent og en basisk komponent, hvilke er i stand til at moussere. Ved brug, når organet er i et væskemiljø, suges væske ind i det drevne 30 organ, hvorved parret fugtes og bringes til at reagere og frembringe en mousserende opløsning i det drevne organ. Den mousserende opløsning frembringer en neutral tilstand i det drevne organ og dispenserer det aktive middel fra det drevne organ.
35
Dette skrift angår ikke afgivelse af medicinsk aktive midler, der har begrænset opløselighed i surt miljø,og virkningen beror på tilstedeværelse af både den sure og den basiske komponent.
2
Mange betændelsesmodvirkende aktive midler er tungt opløselige i vandholdige og sure miljøer, såsom i mavevæsken, og ved afgivelsen fra et osmotisk drevet organ udfældes disse aktive midler ved berøring med mavevæsken og akkumuleres ved mundin-5 gen af gennemstrømningsåbningen og på den ydre overflade af det drevne organs væg. Det udfældede aktive middel forhindrer opløsningen af midlet i at strømme gennem det osmotisk drevne organs gennemstrømningsåbning.
jø Det osmotisk drevne organ ifølge den foreliggende opfindelse er ejendommeligt ved, at et i rummet indeholdt aktivt middel udviser en begrænset opløselighed i vand og det sure vandige miljø, og at rummet yderligere indeholder en vandopløselig ugiftig basisk,carbondioxidfrembringende forbindelse., der udviser en osmotisk trykgradient på tværs af væggen mod den om-15 givende væske, samt at rummet i det væsentlige er fri for sure bestanddele, der er i stand til at frembringe carbondioxid med den basiske forbindelse. Den carbondioxiddannende forbindelse, der ved frigøring fra det drevne organ kommer i kontakt med 2ø syren i maveregionen, reagerer med denne,og danner carbondioxid. Denne fysiske aktivitet og gassen dispenserer det aktive middel i fin dispergeret form fra organet samtidig med, at det drevne organs gennemstrømningsåbning holdes åben.
Eksempelvise udførelsesformer for opfindelsens genstand be-25 skrives nedenfor på grundlag af tegningen. I denne viser fig. 1 i ukorrekt målestok i delvis åbnet tilstand et osmotisk drevet organ fremstillet med en semipermeabel væg benyttet til at administrere et aktive middel, 30 fig. 2 i ukorrekt målestok i delvis åbnet tilstand et osmotisk drevet organ fremstillet med en semipermeabel mikroporøs væg benyttet til at administrere et aktivt middel, fig. 3 frigørelsesmønstret for et vanskeligt opløseligt ak-3 5 tivt middel fra et osmotisk drevet organ frigivet uden gasdannende forbindelse, og fig. 4 frigivelsesmønstret for et vanskeligt opløseligt aktivt middel fra et osmotisk drevet organ frigivet med en gasdan-
DK 152482 B
3 nende forbindelse.
Fig. 1 viser en udførel sesform for et osmotisk drevet organ 10 benyttet til at administrere et aktivt middel. Det osmotisk drevne organ 10 ses i åbnet tilstand, og omfatter en væg 11 5 dannet af en semipermeabel polymer, der omgiver og danner et rum 12. Der er en gennemstrømningsåbning 13, der forbinder rummet 12 med det drevne organ 10's ydre omgivelser for at administrere et aktivt middel 14, der er angivet ved prikker, og en basisk forbindelse 15, der er gengivet ved streger, og som har en carbondioxiddannende gruppe, fra det drevne organ 10.
Fig. 2 illustrerer en anden udførelsesform for et osmotisk drevet organ 10 benyttet til at administrere et aktivt middel.
Det osmotiske organ 10, der ses i åbnet tilstand, omfatter en 1 5 væg 11 dannet af en semipermeabel polymer, hvorpå der er lamineret et mikroporøst lag 16, der vender mod rummet 12's indre. I en anden ikke vist udførelsesform kan det mikroporøse laminat 16 være på den semipermeable væg 12's ydre overflade. Som vist i fig. 2 har organet 10 en gennemstrømningsåbning 13 gennem det semipermeable mikroporøse laminat dannet ved 11 og 16 for at forbinde rummet 12 med det drevne organ 10’s ydre omgivelser for at administrere et aktivt middel 14 og en carbondioxid dannende forbindelse 15 fra det drevne organ 10. 1 2 3 4 5 6 7 8 9 10 11
Det osmotisk drevne organ 10's semipermeable væg er dannet af 2 et semipermeabelt materiale, der ikke på uheldig måde påvirker 3 det aktive middel, den carbondioxid dannende forbindelse,el ler 4 patienten. Den semipermeable væg er dannet af et polymert ma 5 teriale, der er permeabelt for passage af vand og er i det 6 væsentlige uigennemtrængelig for passage af aktive midler, 7 opløste produkter og tilsvarende stoffer. De selektivt permea 8 ble polymerer, der er egnede til fremstilling af drevne orga 9 ner , repræsenteres ved et stof valgt fra den gruppe, der består 10 af celluloseacylat, cellulosediacylat, cellulosetriacylat, 11 celluloseacetat, cel 1ulosediacetat, cellulosetriacetat, polyamider, polyurethaner og tilsvarende stoffer. Passende semipermeable polymerer til fremstilling af osmotisk drevne organer er beskrevet i US-patentskrift nr. 3.845.770, 3.916.899,
DK 152482 B
4 4.008.719, 4.036.228 og 4.111.210. I den i fig. 2 viste udførelsesform kan den semipermeable væg 12 være et laminat indbefattende et semipermeabelt lag 11 arrangeret til et laminat sammen med et mikroporøst lag 16. Det semipermeable lag 11 er 5 formet ud fra en af de oven for beskrevne polymere. Det mikro-porøse lag 16 har en mængde mikroporer og indbyrdes forbundne mikroveje for at tilføre væske ind i indretningen. Det mikro-porøse lag kan indbefatte de oven for omtalte polymere omfattende en poredanner, der opløses, eller udvaskes fra laget, 10 når det drevne organ er i drift i brugsmiljøet. Poredannerne er ugiftige og de kan ikke reagere med de materialer, der danner væggen. Når de fjernes fra laget, fyldes de deri dannede veje med væske, og disse veje bliver et organ for væskeindstrømning i organet. Typiske poredannere repræsenteres 15 ved natriumchlorid, kaliumchlorid, sorbitol, mannitol, polye- thylenglycol, hydroxypropylmethylcellulose, hydroxypropylbu-tylcellulose, og tilsvarende stoffer. Osmotisk drevne organer med en lamineret væg indbefattende et semipermeabelt lag og et mikroporøst lag er beskrevet i US-patentskrift nr. 4.160.452.
20
Udtrykket aktivt middel som brugt her omfatter stort set forbindelser, stofsammensætninger eller blandinger deraf, der kun vanskeligt kan opløses i væsken og som kræver dannelsen af gasturbulens for at forhindre udfældning og tilstopning af gennemstrømningsåbningen og som således kan administreres fra det drevne organ til at frembringe et gunstigt og nyttigt resultat. Betegnelsen aktivt middel omfatter især ethvert stof, der frembringer en lokal eller systemisk virkning i dyr, fugle, fisk og reptiler. Betegnelsen dyr indbefatter primater, gg mennesker, hus-, sports- og landbrugsdyr, såsom geder, kvæg, heste, hunde, katte og tilsvarende dyr. Betegnelsen dyr indbefatter også laboratoriedyr, såsom mus, rotter og marsvin. De aktive midler, der kan administreres ved fremgangsmåden ifølge opfindelsen omfatter uorganiske og organiske aktive midler, 35 såsom aktive midler, der virker på det centrale nervesystem, hypnotika, sedativer, psykisk aktiverende stoffer, beroligelsesmidler, depressionsmodvirkende stoffer, krampemodvirkende stoffer, muskelafslapningsstofer, stoffer til at modvirke par-
DK 152482 B
6 kinsonsymptomer, bedøvelsesmidler, betændelsesbekæmpende midler, lokalt bedøvende stoffer, malariabekæmpende stoffer, hormoner, sympathomimetika, dioretika, anti paras i tika, neoplasti-ka, hypoglycenika, øjenmedikamenter, hjertemedikamenter, næ-5 ringsmidler og tilsvarende stoffer.
I en mere foretrukken form omfatter betegnelsen aktive midler, der er praktisk taget uopløselige, eller har en begrænset opløselighed i neutralt og surt miljø. Dvs. at disse aktive midler udfældes i sådanne miljøer. Udtrykket neutralt indbefatter vand og tilsvarende biologiske miljøer, og udtrykket sur indbefatter maven og den der frembragte saltsyre, vagina, og den deri frembragte mælkesyre, og tilsvarende. Betegnelsen sur legemesvæske som benyttet her angiver mavevæske, vaginal væske og tilsvarende sure miljøer i et dyrelegeme.
En speciel gruppe af aktive midler egnet til administration til de oven for angivne miljøer ved fremgangsmåden ifølge opfindelsen er de sure betændelsesmodvirkende aktive midler. De betændelsesmoedvirkende aktive midler kan omfatte arylcarbo- 20 xylsyremedikamenter og enolsyremedikamenter. Eksempler på arylcarboxylsyremidler omfattende alclofenac- eller 4-allyl- oxy-3-chlorphenyleddikesyre, aspirin eller acetylsalicylsyre, fenoprofen eller dl-2-(3-phenoxypheny1)propionsyre, flufena- minsyre eller 2-(3-trif1uormethylani1 i no)benzoesyre, ibuprofen 25 eller 2(4-isobutylphenyl)prop ionsyre, indomethacin eller 5-me-thoxy-2-methyl-l-(4'-chlorbenzoyl)-3-i ndo 1 eddikesyre, keto- profen eller 2-(3-benzoyl phenyl)propionsyre, metiazinsyre eller 10-methyl-2-phenothiazinyleddikesyre, naproxen eller d-2-(6'-methoxy-2'-naphthyl)propionsyre, nifluminsyre eller 30 3-trif1uormethyl-2-phenyl ami non i kot i nsyre, tolmetin eller l-methyl-5-p-toluoylpyrrol-2-eddikesyre, og sulindac- eller cis-5-fluor-2-methyl-l-[p-(methylsulfinyl)-benzyliden]i nden- 3-eddikesyre. Eksempler på enolsyremidler omfatter azapropa- zon eller 3-dimethy1 am ino-7-methy1-1,2-(n-propyImalony1)-1,2-35 dihydro-l,2,4-benzotriazin, phenylbutazon eller 3,5-dioxo-4-n-butyl-l,2-diphenylpyrazolidin, prenazon eller 4-preny1-1,2-diphenyl-3,5-pyrazoli dindion, sudoxicam eller 4-hydroxy-2-
DK 152482 B
6 methyl-N-(2-thiazoly1)-2H-1,2-benzothi azi n-3-carboxami d-1,1-dioxid og lignende. Andre betændelsesmodvirkende aktive midler omfatter diclofenac eller 2-[2,6-dich1orpheny1)-am i no]-benzeneddikesyre og peroxicam eller 2H-1,2-benzothiazin-3-5 carboxamid.
Eksempler på andre aktive midler som er praktisk taget uopløselige eller meget tungt opløselige i vand, og som kan indgives ved hjælp af fremgangsmåden ifølge opfindelsen omfatter diphenidon, meclizinhydroch1 or id, proch1orperazinma1eat, ani-sidon, diphenadion, erythritoltetranitrat, dizoxin, reserpin, acetazolamid, methazolamid, bendroflumethiazid, chlorpropamid, tolazamid, allupurinol, aluminiumaspirin, salicylsyre, natriumsal i cyl at , salicylamid, acetami nophen, acetophenetidin, co-læchicin, mefenamicsyre, oxophenbutazon, zomepirac, methotre-xat, acetylsulfisoxazol, hydrocorti son, desoxycorticosterona-cetat, cortisonacetat, triaminolon, 17-estradion, 17-hydroxy-progesteron, 19-norpreogesteron, prednisolon, progesteron, no-rethindronacetat, norethynodrel og lignende.
20
Den i et drevet organ tilstedeværende mængde af aktivt middel vil variere afhængig af aktiviteten og den mængde af aktivt middel, der skal indgives værtsdyret. Almindeligvis vil det drevne organ rumme fra 0,5 mg til 3 g eller mere, idet enkelte drevne organer f.eks. indeholder 25 mg, 50 mg, 125 mg, 250 mg, 25 1,5 g og lignende. Det aktive middel kan foreligge i forskellig form i det drevne organ, såsom være dispergeret, granuleret, foreligge i pulverform, som en presset masse, som en hinde og på andre tilsvarende måder. Det aktive middel kan også være blandet med et bindemiddel, et diluenda, et disper-30 geringsmiddel, et stabiliseringsmiddel, farve og tilsvarende stoffer. De gavnlige aktive midler, deres opløselighed og deres doseringsmængde kendes indenfor teknikken fra "Pharmaceutical Sciences", af Remington, 15. udgave 1975, udgivet af
Mack Publishing Co., Easton, Penna.; "The Drug, the Nurse, the 3 5
Patient, Including Current Drug Handbook" 1974-1976 ved Falconer m.fl. udgivet af Saunder Company, Philadelphia, Penna.; fra "Physician Desk Reference", 33. udgave, 1979, udgivet af
DK 152482B
7
Medical Economics Co., Oradell, N.J.; fra Ann. of Allergy, bind 41, side 75 til 77, 1979; fra "Arzenim. Forsch.", bind 25, side 1629 til 1635, 1975; og fra "J. Inter. Med Res.", bind 7, side 335 til 338, 1979".
5
Den gasdannende forbindelse egnet til den foreliggende opfindelses formål er en vandopløselig, ugiftig, basisk, carbondio-xidfrembringende forbindelse og som a) udviser en osmotisk trykgradient på tværs af den semipermeable væg mod den omgi-10 vende væske og suger væske ind i det drevne organ, b) virker som et puffermiddel og opløses i væsken, der trænger ind i det drevne organ under dannelse af en opløsning, der indeholder et aktivt middel, c) hæver udenfor det drevne organ pH-værdien for det område, der umiddelbart omgiver gennemstrømningsåb-15 ningen, nok til at formindske det aktive middels udfældningshastighed, og d) udenfor det drevne organ ved grænsefladen for gennemstrømningsåbningens omgivelser, reagerer med omgivelsernes syre til at frembringe carbondioxidmoussering, som styrer det aktive middel væk fra det drevne organ i en disper-2Q geret form. De basiske forbindelser indbefatter ugiftige me-talcarbonat og bicarbonatsalte, såsom alkalimetalcarbonater og bicarbonater, de alkaliske jordarters carbonater og bicarbo-nater og blandinger af disse. De foretrukne forbindelser er de, der er vandopløselige og som frembringer en hurtig mousse-25 rende virkning ved berøring med miljøets syre. Man kan benytte en blanding af forbindelser med forskellige opløsningsgrader i vand, hvoraf mindst én forbindelse er meget 1 et opløselig i vand. Eksempelvise forbindelser indbefatter lithiumcarbonat, natriumcarbonat, ka1 iumcarbonat, 1ithiumbicarbonat, natriumbi-30 carbonat, kaliumbicarbonat, magniumcarbonat, calciumcarbonat, magniumbicarbonat, calciumcarbonat, magniumbicarbonat og tilsvarende stoffer. Forbindelser, der også danner en nyttig gas, er ammon iumcarbonat, ammoniumbicarbonat, ammon i umsesqui carbonat, natriumsesquicarbonat og tilsvarende stoffer. Disse for-3g bindeiser har opløst i vand en pH-værdi større end 7, almindeligvis mellem 8 og 12. Valgfrit er det hyppigt ønskeligt at vælge det aktive middel og forbindelsen uden en fælles ioneffekt, således at deres pågældende opløseligheder i en væske,
DK 152482 B
8 der strømmer ind i det drevne organ, er maksimale. Mængden af basisk forbindelse eller blanding af sådanne i hulrummet, andrager almindeligvis ca. 0,5 mg til 3 g eller mere, og er fortrinsvis 25 mg til 750 mg. Forbindelserne og deres opløselig-5 hed i vand fremgår af "The Handbook of Chemistry and Physics", 48. udgave, 1968 udgivet af the Chemical Rubber Co., Cleveland, Ohio.
Det aktive middel og den basiske forbindelse kan også benyttes blandet med et bindemiddel og et smøremiddel. Det aktive middel og forbindelsen blandes i et vandopløseligt bindemiddel, og eller i et vanduopløseligt bindemiddel, der frigør det aktive middel og forbindelsen ved berøring med vand.
Typiske vandopløselige bindemidler omfatter poly(ethylengly-15 col), gelatine, agar, carboxycellulose, ethylmethylcellulose, poly(vinylalkohol), poly(vinylpyrrolidon) , vandopløselig stivelsesderivater og tilsvarende stoffer. Typiske smøremidler indbefatter stearinsyre, magniumstearat, zinkstearat og tilsvarende stoffer. Den benyttede mængde af bindemiddel eller 20 smøremiddel er almindeligvis ca. 0,1 mg til 150 mg, eller mere.
De osmotisk drevne organer ifølge opfindelsen fremstilles ved standardfremstillingsmetoder. I én udførelsesform blandes det 25 aktive middel f.eks. med den basiske forbindelse og andre ingredienser ved hjælp af en kuglemølle, ved kalandrer ing, omrøring og presning til en kerne med forudvalgt form. Det drevne organs vægdannende materiale kan påføres ved at dyppe, forme eller sprøjte den pressede blanding. En fremgangsmåde 30 til påføring af væggen er luftlægnings- eller luftsuspensionsteknikken, ved hvilken en strøm af atmosfærisk luft og en opløsning af belægningsmidlet ledes forbi det drevne organs i forvejen pressede kerne, der tumler rundt i luftsuspensionen for på alle sider at belægge kernen med en væg. Luftsuspen-35 sionsteknikken kan benyttes til at fremstille en væg dannet af et enkelt lag eller dannet af et andet lag. Luftsuspensionsteknikken er beskrevet i J. Am. Pharm. Assoc.", bind 48, side 451 til 459, 1959 og i bind 49, side 82 til 84, 1960. En osmo-
DK 152482 B
9 tisk gennemstrømningsåbning eller et hul gennem væggen fremstilles ved mekanisk boring, laserboring, stansning eller skæring ved et lokkestempel. Fremgangsmåder til formning af gennemstrømningsåbningen under brug af en laser fremgår af US-5 patentskrift nr. 3.916.899 og 4.088.864. Andre standardfremsti 11ingsfremgangsmåder er beskrevet i "Modern Plastic Encyclopedia", bind 46, side 62 til 70, 1969, i "Remingtons
Pharmaceutical Sciences", 14. udgave, side 1649 til 1698, 1970, udgivet af Mack Publishing Co., Easton, Penna., og i 10 "The Therapy and Practise of Industrial Pharmacy", ved Lachman f.fl., side 197 til 225, i 1970, udgivet af Lea & Febiger Co., Philadelphia, Penna.
De efterfølgende eksempler illustrerer den foreligende opfin- , _ delse.
1 o
Eksempel 1
Et oralt osmotisk drevet organ til at indgive et ikke-steoridt betændelsesmodvirkende aktivt middel natri umindomethacin blev 20 fremstillet som følger. En sammensætning af det aktive middel blev tilberedt til at rummes i det aktive organs hulrum ved grundigt at blande 105,2 mg natriumindomethacintrihydrat, 142 mg kaliumbicarbonat, 5,0 mg polyvinylpyrrolidon, og 7,1 mg stearinsyre og derpå presse den homogene blanding, der inde-25 holder aktivt middel og en carbondioxid producerende gruppe og andre ingredienser til en kerne eller pille til udfyldning af organets indre rum. Herefter blev den komprimerede formulering af det aktive middel anbragt i en 1 uftlægn ings- eller -suspensionsmaskine, dvs. en maskine der blander atmosfærisk luft og 30 en opløsning, der danner en væg, og hvor kernen med bl.a. det aktive middel svæver i luften og belægges med opløsningen, så der dannes et mikroporøst lag bestående af 45 vægt% celluloseacetat med et acetyl indhold på 39,8%, 27,5 vægt% hydroxypro-pylmethylcel1ulose og 27,5 vægt% polyethylenglycol 4000. Laget 35 blev påført fra en opløsning i et methylenchlor id - 95% etha-nolopløsningsmidel (80:20 vægt:vægt). Det mikroporøse lag var ca. 0,13 ml tykt.
DK 152482 B
10
Derpå påførtes et ydre semipermeabelt lag på det mikroporøse lag i luftlægnings- eller -suspensionsmaskinen. Den sammensætning, der dannede det semipermeable lag, indbefattede 50 vægt% cel!uloseacetat med et acetyl indhold på 39,8% og 50 5 vægt% celluloseacetat med et acetyl indhold på 32%. Det semipermeable lag blev påført ud fra en opløsningsblanding indeholdende methylenchlorid og 95% ethanol, 80:20 vægt-.vægt. Systemerne blev tørret og en gennemstrømningsåbning på 0,254 mm blev laserboret gennem den laminerede væg. Systemet frigør in-10 domethacin med en hastighed på 8 mg pr. time. Ved drift frigiver det drevne organ en opløsning, der mousserer eller bruser ved berøring med den sure mavevæske ved gennemstrømningsåbningens udløbsende under frembringelse af carbondioxidbobler, der dispergerer det aktive middel i en fnugagtig ti 1 -15 stand.
Eksempel 2
Et oralt osmotisk organ for den regulerede kontinuerte indgift af indomethacin blev fremstillet ved at følge den generelt 20 ovenfor beskrevne fremgangsmåde. I det foreliggende drevne organ indeholdt rummet en formulering af det aktive middel 56,4% kaliumcarbonat, 37,6% natri umindomethacintri hydrat, 3% providon® og 3% stearinsyre. Den kerne, der skal udfylde organets rum, havde efter komprimering en diameter på 7,93 mm, et 25 overfladeareal på 1,6 cm2 og en massefylde på 1,65 g/ml. Det drevne organ havde en lamineret væg med et indre mikroporøst lag bestående i det væsentlige af 45 vægt% cel!uloseacetat med et acetyl indhold på 39,8%, 45 vægt% sorbitol, og 10 vægt% po- lyethylenglycol 400. Laget blev påført ud fra en opløsning in-30 deholdende methylenchlorid i methanol/vand, 62:35:3 pr. vægt.
Et semipermeabelt lag blev lamineret på det mikroporøse lag, hvilket semipermeable lag bestod af 50 vægt% celluloseacetat med et acetyl indhold på 39,8% og 50 vægt% af celluloseacetat med et acetyl indhold på 32%. Laget var påført ud fra en opløs-35 ning bestående af methylenchlorid og methanol 80:20 pr. vægt.
Det mikroporøse lag var 0,127 mm tykt og det semipermeable lag var 0,061 mm tykt. Det drevne organ havde en gennemstrømnings-
DK 152482 B
11 åbning på 0,23 mm og indgav indomethacin med en hastighed på 8 mg/time. Det drevne organ indgiver det aktive middel i det væsentlige fri for hurtig udfældning ved grænsefladen for gennemstrømningsåbningens omgivelser, og på det drevne organs væg 8 i nærheden af gennemstrømningsåbningen.
Eksempel 3
Fremgangsmåden ifølge eksempel 2 blev gentaget under de beskrevne betingelser med undtagelse af, at det mikroporøse lag 10 var 0,0225 mm tykt, det semipermeable lag 0,069 mm tykt og afgivelseshastigheden var 8 mg/time.
Eksempel 4 15 Det osmotisk drevne organ fra eksemplerne 1 og 2 blev fremstillet i dette eksempel, hvori (a) det mikroporøse lag var 0,127 mm tykt., det semipermeable lag var 0,086 mm tykt, og organet havde en afgivelseshastighed på 6 mg/time, og (b) et organ, hvori det mikroporøse lag var 0,127 mm tykt, det semi-2o permeable lag var 0,043 mm tykt og systemet havde en afgivelseshastighed på 12 mg/time.
Eksempel 5
En serie af orale osmotiske drevne organer til at afgive et 25 arylcarboxylsyre, betændelsesmodvirkende aktivt middel i mavetarmkanalen fremstilles ifølge opfindelsen, hvori det drevne organ rummer fra 40-250 mg natriumindomethacin og fortrinvis fra 85 til 125 mg af natri umindomethacintri hydrat ævivalent med 70 til 100 mg indomethacin, fra 50 til 300 mg af kaliumbi-30 carbonat og fortrinvis fra 130 til 190 mg natriumcarbonat, 2 til 20 mg, fortrinsvis 5 til 10 mg bindemiddel og 2 til 20 mg, fortrinsvis 5 til 10 mg smøremiddel. Det drevne organ har et indre mikroporøst lag med en vægt fra 18 til 25 mg med en tykkelse på 0,10 til 0,16 mm, og et ydre semipermeabelt lag, der 35 vejer 6 til 20 mg med en tykkelse på 0,035 til 0,100 mm. Det drevne organ har en gennemstrømningsåbning på 0,18 mm til 0,38 mm, og frigiver medikamentet ved en hastighed på 5 til 15 mg/t i me.
Claims (6)
1. Osmotisk drevet organ til reguleret indgift af et aktivt middel til et vandigt surt miljø, hvilket organ består af en p Π med en gennemstrømningsåbning forsynet semipermeabel polymervæg, der omgiver og danner et rum og er permeabel for passage af vand og i det væsentlige impermeabel for passage af et i rummet indeholdt aktivt middel, kendetegnet ved, at det aktive middel udviser en begrænset opløselighed i vand og 25 det sure vandige miljø, og at rummet yderligere indeholder en vandopløselig ugiftig basisk carbondioxidfrembringende forbindelse, der udviser en osmotisk trykgradient på tværs af væggen mod den omgivende væske, samt at rummet i det væsentlige er fri for sure bestanddele, der er i stand til at frembringe 3 0 carbondioxid med den basiske forbindelse.
2. Osmotisk drevet organ til reguleret indgift af et aktivt middel ifølge krav 1, kendetegnet ved, at den basiske forbindelse med en carbondioxiddannende gruppe er et 35 farmaceutisk accepterbart carbonat eller bicarbonat af et alkalimetal eller et jordalkalimetal.
3. Osmotisk drevet organ til reguleret indgift af et aktivt middel ifølge krav 1, kendetegnet ved, at den semi- DK 152482 B permeable polymervæg er belagt med et mikroporøst lag.
4. Osmotisk drevet organ til reguleret indgift af et aktivt middel ifølge krav 1, kendetegnet ved, at den car- _ bonxiddannende forbindelse i rummet er 1 i thiumcarbonat, natri-umcarbonat, ammon iumcarbonat, kaliumcarbonat, 1 ithiumbicarbo- nat, natriumbicarbonat, ammoniumbicarbonat, eller kaliumbicar-bonat.
5. Osmotisk drevet organ til indgift af et aktivt middel 10 ifølge krav 1, kendetegnet ved, at det polymere materiale, der danner den semipermeable væg, er celluloseacylat, cel 1u1 osed iacy1 at eller ce11u1osetriacy1 at.
6. Osmotisk drevet organ til reguleret indgift af et aktivt 15 middel ifølge krav 1, kendetegnet ved, at der på den semipermeable væg er påført et mikroporøst lag dannet af en cellulosepolymer indeholdende en poredanner. 20 25 30 35
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/143,644 US4265874A (en) | 1980-04-25 | 1980-04-25 | Method of delivering drug with aid of effervescent activity generated in environment of use |
US14364480 | 1980-04-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK184681A DK184681A (da) | 1981-10-26 |
DK152482B true DK152482B (da) | 1988-03-07 |
DK152482C DK152482C (da) | 1988-08-01 |
Family
ID=22504961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK184681A DK152482C (da) | 1980-04-25 | 1981-04-24 | Osmotisk drevet organ til reguleret indgift af et aktivt middel til et vandigt, surt vaeskemiljoe |
Country Status (11)
Country | Link |
---|---|
US (1) | US4265874A (da) |
EP (1) | EP0040899B1 (da) |
JP (1) | JPS56167617A (da) |
AT (1) | ATE9267T1 (da) |
DE (1) | DE3165901D1 (da) |
DK (1) | DK152482C (da) |
ES (2) | ES267593Y (da) |
GR (1) | GR73519B (da) |
IE (1) | IE51216B1 (da) |
NZ (1) | NZ196561A (da) |
PT (1) | PT72796B (da) |
Families Citing this family (707)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
US4344929A (en) * | 1980-04-25 | 1982-08-17 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
JPS5770816A (en) * | 1980-10-17 | 1982-05-01 | Ono Pharmaceut Co Ltd | Multilayered film preparation of prostagladin of prolonged action |
FR2525474A1 (fr) * | 1982-04-26 | 1983-10-28 | Roussel Uclaf | Nouvelle forme pharmaceutique orale de clometacine |
US4478596A (en) * | 1982-11-26 | 1984-10-23 | Michelson Paul E | Delivery system for physiologically active agents |
US4613330A (en) * | 1982-11-26 | 1986-09-23 | Michelson Paul E | Delivery system for desired agents |
NZ206600A (en) * | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
JPH075457B2 (ja) * | 1983-08-16 | 1995-01-25 | ザ ウエルカム フアウンデ−シヨン リミテツド | 調節された方法による有効成分の放出を可能にする医薬組成物 |
US4670578A (en) * | 1983-08-29 | 1987-06-02 | Merck & Co., Inc. | Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters |
EP0137364A3 (en) * | 1983-09-23 | 1986-10-22 | Merck & Co. Inc. | Suppository form of an osmotic therapeutic system |
US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
GB2150434B (en) * | 1983-12-01 | 1987-11-04 | Alza Corp | Constant rate release systems |
GB2150830B (en) * | 1983-12-05 | 1987-08-19 | Alza Corp | Drug dispenser |
US4725427A (en) * | 1984-03-13 | 1988-02-16 | Albion International, Inc. | Effervescent vitamin-mineral granule preparation |
US4717566A (en) * | 1984-03-19 | 1988-01-05 | Alza Corporation | Dosage system and method of using same |
US4595583A (en) * | 1984-03-19 | 1986-06-17 | Alza Corporation | Delivery system controlled administration of beneficial agent to ruminants |
DE3586445T2 (de) | 1984-06-26 | 1993-01-14 | Merck & Co Inc | Kondensierte benzo-laktam-verbindungen und deren pharmazeutische zusammensetzungen. |
US4693895A (en) * | 1984-10-26 | 1987-09-15 | Alza Corporation | Colon delivery system |
US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
US4627971A (en) * | 1985-04-22 | 1986-12-09 | Alza Corporation | Osmotic device with self-sealing passageway |
US4675174A (en) * | 1985-08-16 | 1987-06-23 | Alza Corporation | Veterinary dispenser delivering beneficial agent by gas power generated in situ |
US4723957A (en) * | 1986-02-07 | 1988-02-09 | Alza Corp. | System for delivering drug with enhanced bioacceptability |
US4971790A (en) * | 1986-02-07 | 1990-11-20 | Alza Corporation | Dosage form for lessening irritation of mocusa |
US4662880A (en) * | 1986-03-14 | 1987-05-05 | Alza Corporation | Pseudoephedrine, brompheniramine therapy |
US4753802A (en) * | 1986-03-19 | 1988-06-28 | Alza Corporation | Verapamil dosage form |
US4847093A (en) * | 1986-06-19 | 1989-07-11 | Alza Corporation | Dosage form with means for governing rate of gas formation |
US4715994A (en) * | 1986-11-05 | 1987-12-29 | Merck & Co., Inc. | Novel antibacterial agents and potentiators of carbapenem antibiotics |
US5143908A (en) * | 1986-11-05 | 1992-09-01 | Merck & Co., Inc. | Antibacterial agents and potentiators of carbapenem antibiotics |
US5099063A (en) * | 1986-11-05 | 1992-03-24 | Merck & Co., Inc. | Certain phosphinic acid derivatives having antibacterial activity |
US5110597A (en) * | 1987-06-25 | 1992-05-05 | Alza Corporation | Multi-unit delivery system |
US5023088A (en) * | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
US5938654A (en) * | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US4957494A (en) * | 1987-06-25 | 1990-09-18 | Alza Corporation | Multi-layer delivery system |
US5499979A (en) * | 1987-06-25 | 1996-03-19 | Alza Corporation | Delivery system comprising kinetic forces |
US4874388A (en) * | 1987-06-25 | 1989-10-17 | Alza Corporation | Multi-layer delivery system |
JPS6413097A (en) * | 1987-07-06 | 1989-01-17 | Mitsubishi Chem Ind | Phosphonic acid derivative |
US5041644A (en) * | 1987-07-06 | 1991-08-20 | Merck & Co., Inc. | Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid |
DE3873278T2 (de) | 1987-09-22 | 1993-02-25 | Merck & Co Inc | Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren. |
US5030732A (en) * | 1988-03-03 | 1991-07-09 | Merck & Co., Inc. | Aminoethylphosphinic acid derivatives |
US5211957A (en) * | 1988-03-25 | 1993-05-18 | Ciba-Geigy Corporation | Solid rapidly disintegrating dosage form |
CH675537A5 (da) * | 1988-03-25 | 1990-10-15 | Ciba Geigy Ag | |
US5145990A (en) * | 1988-10-28 | 1992-09-08 | Merck & Co., Inc. | Phosphorous containing dhp enzyme inhibitors |
US5147867A (en) * | 1988-10-28 | 1992-09-15 | Merck & Co., Inc. | Phosphorus containing enzyme inhibitors |
US4962097A (en) * | 1988-10-28 | 1990-10-09 | Merck & Co., Inc. | Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors |
US4942039A (en) * | 1989-05-09 | 1990-07-17 | Miles Inc. | Effervescent analgesic antacid composition having reduced sodium content |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5089530A (en) | 1990-08-03 | 1992-02-18 | Merck & Co., Inc. | Novel fermentation product with antiparasitic activity |
US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
SG84487A1 (en) | 1991-04-17 | 2001-11-20 | Merck & Co Inc | Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist |
US5198229A (en) * | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
US5223265A (en) * | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5639782A (en) * | 1992-03-04 | 1997-06-17 | Center For Innovative Technology | Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors |
US5434151A (en) * | 1992-08-24 | 1995-07-18 | Cytomed, Inc. | Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase |
DK0650485T3 (da) | 1992-07-13 | 2001-01-22 | Millennium Pharm Inc | 2,5-Diaryltetrahydrothiophener, -furaner og analoger til behandling af inflammatoriske forstyrrelser og immunforstyrrelser |
US5463083A (en) * | 1992-07-13 | 1995-10-31 | Cytomed, Inc. | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
US5498255A (en) * | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
US5403952A (en) * | 1993-10-08 | 1995-04-04 | Merck & Co., Inc. | Substituted cyclic derivatives as novel antidegenerative agents |
US5750565A (en) | 1995-05-25 | 1998-05-12 | Cytomed, Inc. | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
US5792776A (en) * | 1994-06-27 | 1998-08-11 | Cytomed, Inc., | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
US5703093A (en) * | 1995-05-31 | 1997-12-30 | Cytomed, Inc. | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
US6348571B1 (en) | 1994-09-12 | 2002-02-19 | Northwestern University | Corticotropin release inhibiting factor and methods of using same |
US5767113A (en) * | 1995-05-10 | 1998-06-16 | The Salk Institute For Biological Studies | Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
KR19990014865A (ko) * | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US5817335A (en) * | 1995-05-26 | 1998-10-06 | Alza Corporation | Osmotic device with high drug loading and delayed activation of drug delivery |
US5741815A (en) * | 1995-06-02 | 1998-04-21 | Lai; Ching-San | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor |
US5756540A (en) * | 1995-06-02 | 1998-05-26 | Mcw Research Foundation, Inc. | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor |
US5800422A (en) * | 1995-06-02 | 1998-09-01 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
US6372713B1 (en) * | 1995-09-08 | 2002-04-16 | The Board Of Trustees Of Northwestern University | Anti-depressant effects of corticotropin release inhibiting factor |
US5747532A (en) * | 1995-11-21 | 1998-05-05 | Medinox, Inc. | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor |
US6723531B2 (en) * | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US5902605A (en) * | 1996-04-18 | 1999-05-11 | Alza Corporation | Drug delivery device with minimal residual drug retention |
US5785688A (en) * | 1996-05-07 | 1998-07-28 | Ceramatec, Inc. | Fluid delivery apparatus and method |
US5939460A (en) * | 1996-07-08 | 1999-08-17 | Idun Pharmaceuticals, Inc. | Method of inhibiting NADPH oxidase |
US5677318A (en) * | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
US5922761A (en) * | 1996-09-06 | 1999-07-13 | Medinox, Inc. | Methods for in vivo reduction of iron levels and compositions useful therefor |
CA2265877A1 (en) | 1996-09-10 | 1998-03-19 | Medinox, Inc. | Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications |
US5858402A (en) * | 1997-02-11 | 1999-01-12 | Medinox, Inc. | Methods for in vivo reduction of cyanide levels and compositions useful therefor |
US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
US5985592A (en) * | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
US5840721A (en) * | 1997-07-09 | 1998-11-24 | Ontogen Corporation | Imidazole derivatives as MDR modulators |
US7105496B2 (en) * | 1998-07-23 | 2006-09-12 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
US6797691B1 (en) | 1997-07-23 | 2004-09-28 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
CA2305703A1 (en) | 1997-10-10 | 1999-04-22 | David W. Christianson | Compositions and methods for inhibiting arginase activity |
US6358536B1 (en) | 1997-10-15 | 2002-03-19 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
US6750201B1 (en) * | 1997-10-17 | 2004-06-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator |
US6756491B2 (en) | 1998-01-09 | 2004-06-29 | The Salk Institute For Biological Studies | Steroid-activated nuclear receptors and uses therefor |
US6984773B1 (en) | 1998-01-09 | 2006-01-10 | The Salk Institute For Biological Studies | Transgenic mice expressing a human SXR receptor polypeptide |
AU3087099A (en) * | 1998-03-16 | 1999-10-11 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
US6287605B1 (en) * | 1998-04-17 | 2001-09-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods useful in treatment and prevention of HIV-1 infection |
WO1999058640A2 (en) | 1998-05-11 | 1999-11-18 | Philadelphia Health And Education Corporation | Mct-1, a human oncogene |
US6333318B1 (en) * | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US20050203187A1 (en) * | 1998-06-01 | 2005-09-15 | Verbiscar Anthony J. | Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof |
US6596770B2 (en) | 2000-05-05 | 2003-07-22 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
US6265420B1 (en) | 1998-06-23 | 2001-07-24 | Medinox, Inc. | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide |
US20030064917A1 (en) * | 1998-07-23 | 2003-04-03 | Crawford Susan E. | Methods and compositions for inhibiting angiogenesis |
US6565854B2 (en) | 1998-08-13 | 2003-05-20 | Philadelphia Health And Education Corporation | Antimicrobial histone H1 compositions, kits, and methods of use thereof |
WO2000009118A1 (en) | 1998-08-13 | 2000-02-24 | The Wistar Institute | Methods for reducing atherosclerotic plaques |
US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US20020138856A1 (en) * | 1998-10-23 | 2002-09-26 | Northwestern University | Compositions and methods useful for treatment of depressive disorder based on an animal model |
NZ512676A (en) | 1999-01-13 | 2003-01-31 | Meditech Res Ltd | A composition and method for the enhancement of the efficacy of drugs |
US7282489B2 (en) * | 2000-01-19 | 2007-10-16 | The Children's Hospital Of Philadelphia | Compositions and methods for performing reverse gene therapy |
WO2000041731A1 (en) | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Reverse gene therapy |
US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
EP1157007A1 (en) | 1999-02-25 | 2001-11-28 | Merck Frosst Canada Inc. | Pde iv inhibiting compounds, compositions and methods of treatment |
US6221855B1 (en) | 1999-03-11 | 2001-04-24 | Wake Forest University | Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof |
US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6025502A (en) * | 1999-03-19 | 2000-02-15 | The Trustees Of The University Of Pennsylvania | Enantopselective synthesis of methyl phenidate |
US6251927B1 (en) | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
AU4803800A (en) | 1999-04-27 | 2000-11-10 | Trustees Of The University Of Pennsylvania, The | Compositions, methods, and kits relating to LTiGTresistinLT/iGT |
US6420545B1 (en) | 1999-05-24 | 2002-07-16 | The Trustees Of The University Of Pennsylvania | CD4-independent HIV envelope proteins as vaccines and therapeutics |
US7033780B1 (en) * | 1999-06-14 | 2006-04-25 | Millennium Pharmaceuticals, Inc. | Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein |
US7160694B2 (en) | 1999-06-14 | 2007-01-09 | Millennium Pharmaceuticals, Inc. | Nucleic acids encoding TANGO405 and functional fragments and uses thereof |
US6964854B1 (en) | 1999-07-13 | 2005-11-15 | Science & Technology Corporation | Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis |
US20020147197A1 (en) * | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
WO2001026467A1 (en) | 1999-10-08 | 2001-04-19 | Ontogen Corporation | Methods of enhancing chemotherapy |
ES2339326T3 (es) | 1999-10-12 | 2010-05-19 | Chemocentryx, Inc. | Receptor de quimioquina. |
US6274627B1 (en) | 1999-10-12 | 2001-08-14 | Medinox, Inc. | Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor |
US7057015B1 (en) | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
JP3417370B2 (ja) | 1999-12-09 | 2003-06-16 | 株式会社村田製作所 | 非可逆回路素子及び通信機装置 |
US6559128B1 (en) | 2000-01-21 | 2003-05-06 | Northwestern University | Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof |
US20030212021A1 (en) * | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
US6464688B1 (en) | 2000-02-15 | 2002-10-15 | Microsolutions, Inc. | Osmotic pump delivery system with flexible drug compartment |
JP2001320205A (ja) | 2000-03-02 | 2001-11-16 | Murata Mfg Co Ltd | 非可逆回路素子および通信装置 |
US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
DE60123232T2 (de) * | 2000-04-07 | 2007-11-08 | Trustees Of The University Of Pennsylvania | Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung |
US6509315B1 (en) | 2000-04-07 | 2003-01-21 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
EP1282614B1 (en) * | 2000-05-15 | 2003-11-12 | Darwin Discovery Limited | Hydroxamic acid derivatives |
US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
US7087632B2 (en) * | 2001-03-05 | 2006-08-08 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
WO2001091730A1 (en) | 2000-05-31 | 2001-12-06 | Drugtech Corporation | Mineral supplement |
US6833357B2 (en) * | 2000-06-20 | 2004-12-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulating muscle cell and tissue contractility |
US6429223B1 (en) | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
US9066919B2 (en) * | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
EP2184296A1 (en) | 2000-07-19 | 2010-05-12 | Advanced Research And Technology Institute, Inc. | Fibroblast growth factor (fgf23) and methods for use |
AU2001290629A1 (en) * | 2000-09-07 | 2002-03-22 | Boehringer Ingelheim International G.M.B.H | Heat shock response and virus replication |
US7538097B2 (en) * | 2000-09-26 | 2009-05-26 | Halozyme, Inc. | Inhibition of antigen presentation with poorly catabolized polymers |
US20040102367A1 (en) * | 2001-02-23 | 2004-05-27 | Gage Fred H | Gene expression system based on chimeric receptors |
AU2002248557A1 (en) * | 2001-03-05 | 2002-09-19 | Transtech Pharma, Inc. | High level insect expression of rage proteins |
WO2002070473A2 (en) * | 2001-03-05 | 2002-09-12 | Transtech Pharma, Inc. | Carboxamide derivatives as therapeutic agents |
US7208279B2 (en) * | 2001-03-14 | 2007-04-24 | Caden Biosciences, Inc. | Method for identifying inhibitors of G protein coupled receptor signaling |
US7294472B2 (en) * | 2001-03-14 | 2007-11-13 | Caden Biosciences | Method for identifying modulators of G protein coupled receptor signaling |
ITMI20010733A1 (it) | 2001-04-05 | 2002-10-05 | Recordati Chem Pharm | Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria |
US6727287B2 (en) | 2001-04-16 | 2004-04-27 | Pts International, Inc. | Toluene sulfonamide-containing anti-tumor composition and method of use thereof |
US6632217B2 (en) * | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
CN1157388C (zh) * | 2001-05-29 | 2004-07-14 | 北京大学 | 哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用 |
RU2259825C9 (ru) | 2001-06-18 | 2006-04-10 | БиоДием Лимитед | Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
AU2002322515A1 (en) * | 2001-07-17 | 2003-03-03 | Keith Choate | Compositions, methods, and kits related to treating and diagnosing hypertension |
GB0119396D0 (en) * | 2001-08-09 | 2001-10-03 | Celltech R&D Ltd | Hydroxamic acid derivatives |
WO2003015757A1 (en) * | 2001-08-16 | 2003-02-27 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
US9056048B2 (en) * | 2001-08-16 | 2015-06-16 | The Trustees Of The University Of Pennsylvania | Synthesis and use of cationic steroids for anti-inflammatory drug therapy |
CN1578677A (zh) * | 2001-08-27 | 2005-02-09 | 美迪泰克研究有限公司 | 改良的治疗方案 |
US20030069071A1 (en) * | 2001-09-28 | 2003-04-10 | Tim Britt | Entertainment monitoring system and method |
PT1436321E (pt) * | 2001-10-19 | 2006-10-31 | Isotechnika Inc | Sintese de analogos de ciclosporina |
US6555563B1 (en) | 2001-11-16 | 2003-04-29 | Medinox, Inc. | Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation |
US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7253007B2 (en) * | 2001-11-30 | 2007-08-07 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7871619B2 (en) * | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7413866B2 (en) * | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
PE20030701A1 (es) * | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
JP2005518391A (ja) | 2001-12-21 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | Gk活性化剤としてのアミド誘導体 |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
US20030161882A1 (en) * | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
TW200302748A (en) * | 2002-02-01 | 2003-08-16 | Pfizer Prod Inc | Osmotic delivery system |
US7378111B2 (en) * | 2002-02-20 | 2008-05-27 | The Trustees Of The University Of Pennsylvania | Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease |
CN101613321A (zh) * | 2002-03-05 | 2009-12-30 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
DE60335869D1 (de) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
US7378438B2 (en) * | 2002-04-19 | 2008-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
CA2484797A1 (en) * | 2002-05-06 | 2003-11-13 | Washington University | Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway |
AUPS234402A0 (en) * | 2002-05-15 | 2002-06-13 | Auckland Uniservices Limited | Anti-tumour polycyclic carboxamides |
US20080051428A1 (en) * | 2002-05-15 | 2008-02-28 | Davis Paul J | Pyrroloquinoline quinone drugs and methods of use thereof |
EP2399903A1 (en) * | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
US6727241B2 (en) | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US7842693B2 (en) * | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
JP4723242B2 (ja) | 2002-06-12 | 2011-07-13 | ケモセントリックス インコーポレーティッド | 炎症および免疫障害治療用ccr1アンタゴニストとして使用するための1−アリール−4−置換ピペラジン誘導体 |
US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
US20040077691A1 (en) * | 2002-06-21 | 2004-04-22 | Medinox, Inc. | Hydroxamate derivatives of non-steroidal anti-inflammatory drugs |
US6620813B1 (en) | 2002-06-21 | 2003-09-16 | Medinox, Inc. | Hydroxamate derivatives of non-steroidal anti-inflammatory drugs |
JP4881559B2 (ja) | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | 治療薬としてのアリールカルボニル誘導体 |
EP2210892A3 (en) | 2002-10-04 | 2010-10-27 | Prana Biotechnology Limited | Neurologically-active compounds |
AU2003284166A1 (en) * | 2002-10-23 | 2004-05-13 | University Of Hawaii | Methods for diagnosing and treating pre-term labor |
EP1562975A2 (en) * | 2002-10-25 | 2005-08-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
JP2006511500A (ja) | 2002-10-30 | 2006-04-06 | メルク エンド カムパニー インコーポレーテッド | γ−アミノアミド系のケモカイン受容体活性調節剤 |
AU2003275939A1 (en) | 2002-11-08 | 2004-06-07 | Novo Nordisk A/S | Safe chemical uncouplers for the treatment of obesity |
US20050143449A1 (en) * | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
US20070021466A1 (en) * | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US7741519B2 (en) * | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
ES2369720T5 (es) | 2002-11-18 | 2014-11-06 | Chemocentryx, Inc. | Arilsulfonamidas |
US7227035B2 (en) * | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
AU2003293006A1 (en) * | 2002-11-22 | 2004-06-18 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
AU2003286389A1 (en) * | 2002-11-29 | 2004-06-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ace-inhibitors having antioxidant and nitricoxid-donor activity |
EP1606251B1 (en) * | 2002-12-20 | 2009-04-08 | ChemoCentryx Inc | Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor |
EP1572672B1 (en) | 2002-12-20 | 2008-08-13 | Sosei R&D Ltd. | Benzoxazocines and their use as monoamine-reuptake inhibitors |
AU2004204751A1 (en) * | 2003-01-09 | 2004-07-29 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
AU2003900927A0 (en) * | 2003-02-28 | 2003-03-13 | Biodiem Ltd | Growth promotion method |
WO2004084812A2 (en) * | 2003-03-21 | 2004-10-07 | Joullie Madeleine M | Tamandarin analogs and fragments thereof and methods of making and using |
EP2239012A3 (en) | 2003-04-11 | 2011-06-15 | High Point Pharmaceuticals, LLC | Substituted amide derivatives and pharmaceutical uses thereof |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
WO2004100929A1 (en) | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
MXPA05012350A (es) * | 2003-05-20 | 2006-05-25 | Transtech Pharma Inc | Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma. |
PL1656372T3 (pl) * | 2003-07-30 | 2013-08-30 | Rigel Pharmaceuticals Inc | Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym |
WO2005013907A2 (en) * | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
JP2007501813A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | 新生血管形成と関連した症状を治療および診断するためのインターロイキン−20 |
US8071535B2 (en) * | 2003-09-12 | 2011-12-06 | The Regents Of The University Of California | Guanidinium derivatives for improved cellular transport |
WO2005033297A1 (en) * | 2003-09-19 | 2005-04-14 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
BRPI0414890A (pt) | 2003-09-30 | 2006-12-12 | Novo Nordisk As | composto, métodos de retardar a progressão de igt para diabete tipo 2, e de diabete tipo 2 para diabete que requer insulina, de tratar a obesidade ou prevenir o excesso de peso, de regular o apetite, de induzir saciedade, de impedir o ganho de peso, de aumentar o gasto de energia, e de tratar uma doença ou estado, composição farmacêutica, e, uso de um composto |
ES2428358T3 (es) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
US20100247540A1 (en) * | 2003-10-30 | 2010-09-30 | Chemocentryx, Inc. | Methods and Compositions For Modulating Angiogenesis |
WO2005058280A2 (en) * | 2003-12-12 | 2005-06-30 | Myogen, Inc. | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
NZ548399A (en) * | 2003-12-15 | 2011-01-28 | Theramex | 1-N-phenyl-amino-1H-imidazole derivatives and pharmaceutical compositions containing them |
EP2444397A1 (en) | 2004-01-06 | 2012-04-25 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
US7435831B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
CA2558211C (en) * | 2004-03-03 | 2013-09-03 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
US20060003020A1 (en) * | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
EA200601743A1 (ru) | 2004-03-19 | 2007-08-31 | Йел Юниверсити | Выделенный полипептид реналазы и его применение |
US20060025463A1 (en) * | 2004-03-22 | 2006-02-02 | Michael Bristow | Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases |
CA2560538A1 (en) * | 2004-03-22 | 2005-10-06 | Myogen, Inc. | (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases |
US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
CA2568622C (en) * | 2004-06-01 | 2016-01-26 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
RU2007101074A (ru) | 2004-06-14 | 2008-07-20 | Зозер Б. САЛАМА (DE) | Фармацевтическая противораковая композиция пролина или его производных и противоопухолевого антитела |
US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
CA2572179A1 (en) * | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
JP5065019B2 (ja) * | 2004-06-24 | 2012-10-31 | ウィスコンシン アルムニ リサーチ ファンデイション | 新生糖ランダム化及びジギトキシン類似体 |
US8507411B2 (en) * | 2004-06-24 | 2013-08-13 | Wisconsin Alumni Research Foundation | Neoglycorandomization and digitoxin analogs |
AU2005270229B2 (en) * | 2004-07-02 | 2012-04-12 | Allergan, Inc. | Prostaglandin analogs |
US20090060925A1 (en) * | 2004-08-03 | 2009-03-05 | The Trustees Of Columbia University In The City Of | Rage Fusion Proteins and Methods of Use |
US7101904B2 (en) * | 2004-08-10 | 2006-09-05 | Allergan, Inc. | Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US7183310B2 (en) * | 2004-08-10 | 2007-02-27 | Allergan, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US7906552B2 (en) * | 2004-08-10 | 2011-03-15 | Allergan, Inc. | Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
WO2006137839A2 (en) | 2004-08-24 | 2006-12-28 | Merck & Co., Inc. | Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |
KR20070054246A (ko) * | 2004-09-17 | 2007-05-28 | 유니버시티 오브 매사추세츠 | 리소좀성 효소 결핍을 위한 조성물 및 이의 용도 |
US20080096859A1 (en) * | 2004-10-01 | 2008-04-24 | Sullivan Kathleen A | Compositions and Methods for Treating Ophthalmic Diseases |
EP1647549A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
US7612082B2 (en) * | 2004-10-28 | 2009-11-03 | Allergan, Inc. | Prostaglandin EP4 antagonists |
US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
EP1824835A1 (en) | 2004-12-03 | 2007-08-29 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
WO2006074265A2 (en) * | 2005-01-06 | 2006-07-13 | Merck & Co., Inc. | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
US20060173019A1 (en) | 2005-01-14 | 2006-08-03 | Solomon Ungashe | Heteroaryl sulfonamides and CCR2 |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
TWI386208B (zh) * | 2005-04-18 | 2013-02-21 | Allergan Inc | 治療性的經取代環戊酮 |
MX2007013108A (es) * | 2005-04-21 | 2008-04-07 | Chemocentryx Inc | Reactivos que enlazan ccx-ckr2. |
JP5774264B2 (ja) | 2005-04-27 | 2015-09-09 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中glp−1レベルを増大させることによって緩和される病態の処置のための、併用療法 |
WO2006121708A1 (en) * | 2005-05-06 | 2006-11-16 | Allergan, Inc. | Substituted beta-lactams and their use in medicine |
EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
PL1883394T3 (pl) | 2005-05-23 | 2018-09-28 | Sdg, Inc. | Konstrukt lipidowy do dostarczania insuliny ssakowi |
CN105348203B (zh) | 2005-06-08 | 2018-09-18 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070021357A1 (en) * | 2005-06-17 | 2007-01-25 | Dynamis Therapeutics, Inc. | Treatment of inflammatory conditions |
US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
WO2007002701A2 (en) | 2005-06-27 | 2007-01-04 | Amgen Inc. | Anti-inflammatory aryl nitrile compounds |
WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
ES2422383T3 (es) | 2005-07-14 | 2013-09-11 | Novo Nordisk As | Activadores de urea glucoquinasa |
JP5465431B2 (ja) * | 2005-07-27 | 2014-04-09 | アルケミア オンコロジー ピーティーワイ リミテッド | ヒアルロナンを用いる治療プロトコル |
WO2007021803A1 (en) | 2005-08-12 | 2007-02-22 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
EP1924606A4 (en) | 2005-08-25 | 2010-01-13 | Repair Technologies Inc | DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE |
US8871764B2 (en) | 2005-08-29 | 2014-10-28 | University Of Virginia Patent Foundation | Lisofylline analogs and methods for use |
ATE520657T1 (de) * | 2005-08-29 | 2011-09-15 | Univ Virginia Patent Found | Lisofyllin-analogika und ihre pharmazeutischen verwendungen |
US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
CA2621279C (en) | 2005-09-07 | 2016-06-14 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
US20070178141A1 (en) * | 2005-09-07 | 2007-08-02 | Bebaas, Inc. | Vitamin B12 compositions |
EP1948245B1 (en) * | 2005-10-24 | 2011-10-05 | University of Massachusetts | Compositions and their uses for gene therapy of bone conditions |
CN101355876B (zh) | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | 一种适用于眼部给药的组合物 |
US7557213B2 (en) | 2005-11-10 | 2009-07-07 | Chemocentryx, Inc. | Substituted quinolones and methods of use |
US7427685B2 (en) | 2005-12-06 | 2008-09-23 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
US7585895B2 (en) * | 2005-12-06 | 2009-09-08 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
JP2009520833A (ja) * | 2005-12-20 | 2009-05-28 | ギリード・コロラド・インコーポレーテッド | 4,7−ジヒドロチエノ[2,3−b]ピリジン化合物及び医薬組成物 |
US7323477B2 (en) * | 2006-02-02 | 2008-01-29 | Allergan, Inc. | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline |
CN101437503A (zh) * | 2006-02-21 | 2009-05-20 | 阿斯特鲁姆医疗有限公司 | 用于降低血糖水平和治疗糖尿病的组合物 |
JP2009528295A (ja) * | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
EP1996546B1 (en) | 2006-03-20 | 2014-11-26 | Allergan, Inc. | Substituted gamma lactams as prostaglandin ep2 agonists |
US20070225246A1 (en) * | 2006-03-27 | 2007-09-27 | Denu John M | O-acetyl-ADP-ribose non-hydrolyzable analogs |
ES2354390T3 (es) * | 2006-04-11 | 2011-03-14 | Arena Pharmaceuticals, Inc. | Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo. |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
AU2007240120A1 (en) | 2006-04-14 | 2007-10-25 | Prana Biotechnology Ltd | Method of treatment of age-related macular degeneration (AMD) |
US7439372B2 (en) | 2006-05-03 | 2008-10-21 | Allergan, Inc. | Therapeutic compounds |
US20090016981A1 (en) | 2006-05-03 | 2009-01-15 | Allergan, Inc. | Therapeutic compounds |
US7476755B2 (en) | 2006-05-04 | 2009-01-13 | Allergan, Inc. | Therapeutic compounds |
JP4435288B2 (ja) | 2006-05-09 | 2010-03-17 | メルク エンド カムパニー インコーポレーテッド | 置換スピロ環cgrp受容体アンタゴニスト |
US7547727B2 (en) | 2006-05-22 | 2009-06-16 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
US7553860B2 (en) * | 2006-06-14 | 2009-06-30 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
CN101511795B (zh) | 2006-07-05 | 2013-09-18 | 安万特农业公司 | 1-芳基-5-烷基吡唑衍生化合物、其制备方法和使用方法 |
JP5532302B2 (ja) | 2006-07-10 | 2014-06-25 | アラーガン インコーポレイテッド | 治療化合物 |
US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
PL2046762T3 (pl) | 2006-07-14 | 2011-07-29 | Chemocentryx Inc | Triazolilofenylobenzenosulfonamidy |
US7700627B2 (en) * | 2006-07-26 | 2010-04-20 | Allergan, Inc. | Therapeutic substituted lactams |
WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
US7985767B2 (en) * | 2006-09-06 | 2011-07-26 | Allergan, Inc. | Therapeutic amides |
US7687526B2 (en) | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
WO2008067039A2 (en) * | 2006-10-06 | 2008-06-05 | Wisconsin Alumni Research Foundation | Colchicine neoglycosides and methods for their synthesis and use |
MX2009003821A (es) | 2006-10-10 | 2009-05-25 | Amgen Inc | Compuestos de n-aril pirazol para usarse contra la diabetes. |
PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
US8193373B2 (en) | 2006-12-11 | 2012-06-05 | Allergan, Inc. | Therapeutic compounds |
GB0624757D0 (en) | 2006-12-12 | 2007-01-17 | Sosei R & D Ltd | Novel compounds |
US20100041689A1 (en) | 2006-12-19 | 2010-02-18 | University Of Virginia Patent Foundation | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption |
US20080153881A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders |
US20080153832A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders |
ES2526398T3 (es) | 2006-12-22 | 2015-01-12 | Allergan, Inc. | Composiciones inhibidoras de la recaptación de serotonina-norepinefrina para tratar el dolor crónico |
US20120083508A1 (en) | 2006-12-22 | 2012-04-05 | Allergan, Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
US20080153927A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders |
US20080153880A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders |
US20080153874A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
US20080153825A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders |
US20080153808A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain |
WO2008082217A1 (en) * | 2006-12-28 | 2008-07-10 | Lg Electronics Inc. | Ice making system and method for ice making of refrigerator |
JP5226008B2 (ja) | 2007-01-11 | 2013-07-03 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
US20100221337A1 (en) * | 2007-02-14 | 2010-09-02 | Logical Therapeutics, Inc. | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist |
CA2679301C (en) | 2007-02-28 | 2015-08-11 | University Of Virginia Patent Foundation | Lisofylline analogs and methods for use in protecting pancreatic .beta.-cells, treating type 1 diabetes, and treating inflammatory and autoimmune diseases |
US8563594B2 (en) * | 2007-05-08 | 2013-10-22 | Allergan, Inc. | S1P3 receptor inhibitors for treating pain |
RS60858B1 (sr) | 2007-05-15 | 2020-10-30 | Boehringer Ingelheim Animal Health Usa Inc | Ariloazol-2-il cijanoetilamino jedinjenja, postupci dobijanja i postupci njihove primene |
NZ581405A (en) | 2007-05-22 | 2011-06-30 | Chemocentryx Inc | 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders |
WO2008156721A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Diphenyl substituted alkanes |
US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
CN101820881B (zh) | 2007-07-12 | 2013-05-01 | 坎莫森特里克斯公司 | 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺 |
US20100221334A1 (en) * | 2007-07-19 | 2010-09-02 | Fink Mitchell P | Compositions including leukotriene antagonists and nsaids and methods of using the same |
CN101827828B (zh) | 2007-08-07 | 2013-02-27 | 普罗萨里克斯有限公司 | 作为5-羟色胺能调节剂的1,2,4-三唑衍生物 |
US8846053B2 (en) | 2008-09-26 | 2014-09-30 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
ES2552764T3 (es) | 2007-10-15 | 2015-12-02 | The Salk Institute For Biological Studies | Métodos para el tratamiento de varias enfermedades y afecciones, y compuestos útiles para los mismos |
WO2009052072A1 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
US20110160265A1 (en) * | 2007-10-18 | 2011-06-30 | Luhrs Lauren M B | Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
US8455548B2 (en) * | 2007-10-18 | 2013-06-04 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
WO2009058913A2 (en) * | 2007-10-29 | 2009-05-07 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
US8063033B2 (en) | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
US7956051B2 (en) * | 2008-01-24 | 2011-06-07 | Allergan, Inc. | Therapeutic amides and related compounds |
US8633310B2 (en) * | 2008-02-19 | 2014-01-21 | Allergan, Inc. | Therapeutic substituted lactams |
US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
US7964596B2 (en) * | 2008-03-07 | 2011-06-21 | Allergan, Inc. | Therapeutic compounds |
US20090233921A1 (en) * | 2008-03-11 | 2009-09-17 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
US7960379B2 (en) * | 2008-03-14 | 2011-06-14 | Allergan, Inc. | Therapeutic compounds |
WO2009117335A2 (en) * | 2008-03-17 | 2009-09-24 | Allergan, Inc. | S1p3 receptor inhibitors for treating inflammation |
US7705001B2 (en) * | 2008-03-18 | 2010-04-27 | Allergan, Inc | Therapeutic substituted gamma lactams |
US7732443B2 (en) * | 2008-03-18 | 2010-06-08 | Yariv Donde | Therapeutic substituted cyclopentanes |
US8198318B2 (en) * | 2008-03-18 | 2012-06-12 | Allergen, Inc. | Therapeutic amides |
US7960378B2 (en) * | 2008-03-18 | 2011-06-14 | Allergan, Inc. | Therapeutic compounds |
US7956055B2 (en) * | 2008-03-25 | 2011-06-07 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
EP2146210A1 (en) * | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
EP2278879B1 (en) * | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131951A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
ES2399314T3 (es) * | 2008-04-24 | 2013-03-27 | Allergan, Inc. | Gamma lactamas sustituidas como agentes terapeúticos |
US7964634B2 (en) * | 2008-04-24 | 2011-06-21 | Allergan, Inc. | Therapeutic compounds |
WO2009132097A1 (en) | 2008-04-24 | 2009-10-29 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
US7737140B2 (en) * | 2008-04-24 | 2010-06-15 | Allergan, Inc. | Therapeutic compounds |
US8263593B2 (en) * | 2008-04-24 | 2012-09-11 | Allergan, Inc. | Therapeutic compounds |
CA2728229A1 (en) * | 2008-05-09 | 2009-11-12 | Allergan, Inc. | Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds |
US8530471B2 (en) * | 2008-05-09 | 2013-09-10 | Allergan, Inc. | Therapeutic cyclopentane derivatives |
EP2300439A1 (en) | 2008-05-09 | 2011-03-30 | Allergan, Inc. | Therapeutic substituted hydantoins, and related compounds |
RU2010149492A (ru) * | 2008-05-09 | 2012-06-20 | Аллерган, Инк. (Us) | Терапевтические производные n-арил- или n-гетероарилпиразолидина и пиразолидинона |
BRPI0912193A2 (pt) * | 2008-05-09 | 2015-10-06 | Allergan Inc | compostos terapêuticos. |
US8569349B2 (en) * | 2008-05-09 | 2013-10-29 | Allergan, Inc. | Therapeutic compounds |
US7981887B2 (en) * | 2008-05-09 | 2011-07-19 | Allergan, Inc. | Therapeutic compounds |
AU2009251474B2 (en) * | 2008-05-15 | 2014-06-05 | Allergan, Inc. | Prostaglandin prodrugs as hypotensive agents |
US8124648B2 (en) * | 2008-05-20 | 2012-02-28 | Allergan, Inc. | Therapeutic lactams |
ES2435554T3 (es) * | 2008-05-20 | 2013-12-20 | Allergan, Inc. | Compuestos de prostaglandina terapéuticos utilizados como agentes hipotensores oculares |
AU2009257733A1 (en) | 2008-06-12 | 2009-12-17 | Merck Sharp & Dohme Corp. | Branched 3- and 6-substituted quinolines as CGRP receptor antagonists |
US20100022574A1 (en) * | 2008-07-28 | 2010-01-28 | EndogenX, Inc. | Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist |
JP2012503595A (ja) | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
EP2320906B1 (en) | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
EP2341776A4 (en) * | 2008-09-19 | 2012-05-30 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
EP2186521A1 (en) | 2008-11-14 | 2010-05-19 | Mergemeier Steffen | Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound |
CA2945453C (en) | 2008-11-14 | 2021-03-02 | Merial, Inc. | Enantiomerically enriched aryloazol-2-yl cyanoethylamino paraciticidal compounds |
AU2009316899B2 (en) | 2008-11-19 | 2015-08-20 | Boehringer Ingelheim Animal Health USA Inc. | Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection |
WO2010059618A1 (en) | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
US8426460B2 (en) | 2008-12-04 | 2013-04-23 | Merial Limited | Dimeric avermectin and milbemycin derivatives |
WO2010075257A1 (en) | 2008-12-22 | 2010-07-01 | Chemocentryx, Inc. | C5ar antagonists |
EP2565193B1 (en) | 2009-01-23 | 2014-03-19 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2010093910A1 (en) | 2009-02-13 | 2010-08-19 | Allergan, Inc. | 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
ES2880578T3 (es) | 2009-02-13 | 2021-11-24 | Allergan Inc | Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol |
US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
EP2401269B1 (en) | 2009-02-24 | 2014-01-29 | Merck Sharp & Dohme Corp. | Indole derivatives as crth2 receptor antagonists |
GB0904044D0 (en) | 2009-03-09 | 2009-04-22 | Sosei R & D Ltd | The treatment of inflammatory disorders and pain |
EP2406282A1 (en) | 2009-03-11 | 2012-01-18 | Novo Nordisk A/S | Interleukin-21 variants having antagonistic binding to the il-21 receptor |
US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
US20100256385A1 (en) * | 2009-04-02 | 2010-10-07 | Allergan, Inc. | Prostaglandin e receptor antagonists |
US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
WO2010129686A1 (en) | 2009-05-05 | 2010-11-11 | Vapogenix, Inc. | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
SG10201505101VA (en) | 2009-05-19 | 2015-07-30 | Neuroderm Ltd | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
CA2768356A1 (en) | 2009-07-17 | 2011-01-20 | Allergan, Inc. | Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
RU2557982C2 (ru) | 2009-07-28 | 2015-07-27 | Райджел Фармасьютикалз, Инк. | Композиции и способы ингибирования пути jak |
RU2012105453A (ru) | 2009-08-11 | 2013-09-20 | Аллерган, Инк. | Изотиозолы для лечения состояний глаз |
US20110045522A1 (en) * | 2009-08-20 | 2011-02-24 | Danchen Gao | Methods for diagnosing diabetes and determining effectiveness of treatments |
EP2470181A1 (en) | 2009-08-26 | 2012-07-04 | Allergan, Inc. | Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
BR112012004335A8 (pt) | 2009-09-02 | 2016-06-21 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, uso do composto. |
US9889182B2 (en) | 2009-09-15 | 2018-02-13 | The Regents Of The University Of California | Assisted enzyme replacement therapy |
WO2011035332A1 (en) | 2009-09-21 | 2011-03-24 | Chemocentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators |
JP5805646B2 (ja) | 2009-09-30 | 2015-11-04 | ブイティーブイ・セラピューティクス・エルエルシー | アルツハイマー病の治療のための置換イミダゾール誘導体 |
WO2011066414A1 (en) | 2009-11-25 | 2011-06-03 | Cytometix, Inc. | Arachidonic acid analogs and methods for analgesic treatment using same |
US8846569B2 (en) | 2009-12-04 | 2014-09-30 | Merial Limited | Pesticidal bis-organosulfur compounds |
MX2020001453A (es) | 2009-12-17 | 2021-07-29 | Merial Ltd | Compuestos de dihidroazol antiparasiticos y composiciones que comprenden los mismos. |
WO2011075592A1 (en) | 2009-12-17 | 2011-06-23 | Merial Limited | Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles |
CN102791701B (zh) | 2009-12-30 | 2014-02-12 | 深圳信立泰药业股份有限公司 | 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物 |
CA2788078A1 (en) | 2010-01-26 | 2011-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusale M Ltd. | Compositions and methods for prevention and treatment of pulmonary hypertension |
US9090584B2 (en) | 2010-01-26 | 2015-07-28 | Allergan, Inc. | Therapeutic agents for treatment of ocular hypertension |
US8299068B2 (en) | 2010-01-29 | 2012-10-30 | Allergan, Inc. | Therapeutically active cyclopentanes |
SG183150A1 (en) | 2010-02-03 | 2012-09-27 | Pharma Two B Ltd | Extended release formulations of rasagiline and uses thereof |
GB201002530D0 (en) | 2010-02-15 | 2010-03-31 | Univ Wolverhampton The | Di-aspirin derivatives |
NZ602395A (en) | 2010-02-18 | 2014-05-30 | High Point Pharmaceuticals Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基-雜芳基衍生物及其使用方法 |
EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
WO2011126903A2 (en) | 2010-03-30 | 2011-10-13 | Verseon, Inc. | Multisubstituted aromatic compounds as inhibitors of thrombin |
UA108641C2 (uk) | 2010-04-02 | 2015-05-25 | Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування | |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
US20110288093A1 (en) | 2010-04-20 | 2011-11-24 | Institute For Oneworld Health | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives |
EP2560643A1 (en) | 2010-04-20 | 2013-02-27 | Institute for OneWorld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
CA2798697A1 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
US8980929B2 (en) | 2010-05-21 | 2015-03-17 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
DK2576524T3 (da) | 2010-05-26 | 2018-01-22 | Vtv Therapeutics Llc | Anvendelse af metformin i kombination med en glucokinaseaktivator samt sammensætninger, som omfatter metformin og en glucokinaseaktivator |
US9193989B2 (en) | 2010-06-18 | 2015-11-24 | Taiho Pharmaceutical Co., Ltd. | PRPK-TPRKB modulators and uses thereof |
PL2585064T3 (pl) | 2010-06-24 | 2017-09-29 | Chemocentryx, Inc. | Antagoniści C5AR |
AU2011270872A1 (en) | 2010-06-24 | 2013-01-31 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
US8492424B2 (en) | 2010-07-01 | 2013-07-23 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
US8859606B2 (en) | 2010-07-01 | 2014-10-14 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
IL278149B2 (en) | 2010-07-02 | 2024-03-01 | Univ Virginia Patent Foundation | A molecular genetic approach to the treatment and diagnosis of alcohol and drug dependence |
WO2012003145A2 (en) | 2010-07-02 | 2012-01-05 | Allergan, Inc. | Therapeutic agents for ocular hypertension |
US9714238B2 (en) | 2010-07-02 | 2017-07-25 | Allergan, Inc. | Therapeutic agents for ocular hypertension |
US8343954B2 (en) | 2010-07-28 | 2013-01-01 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
EP2601187A1 (en) | 2010-08-05 | 2013-06-12 | Conrig Pharma ApS | Deuterated tandospirone derivatives as 5-ht1a receptor agonists |
KR101847669B1 (ko) | 2010-08-16 | 2018-05-24 | 알러간, 인코포레이티드 | 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법 |
EP2606044B1 (en) | 2010-08-20 | 2014-06-04 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
WO2012032513A1 (en) | 2010-09-07 | 2012-03-15 | Bar-Ilan University | Boranophosphate derivatives for the treatment of osteoarthritis |
WO2012032524A1 (en) | 2010-09-09 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Near infrared fluorescent particles and uses thereof |
GB201016880D0 (en) | 2010-10-07 | 2010-11-17 | Riotech Pharmaceuticals Ltd | Phosphodiesterase inhibitors |
LT2627328T (lt) | 2010-10-15 | 2016-11-25 | Contera Pharma Aps | Serotonino receptorių agonistų deriniai, skirti judėjimo sutrikimų gydymui |
WO2012058532A2 (en) | 2010-10-28 | 2012-05-03 | Yale University | Methods and compositions for assessing and treating cancer |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
TWI522355B (zh) | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑 |
JP5902705B2 (ja) | 2010-11-15 | 2016-04-13 | ニューロダーム リミテッドNeuroderm Ltd | L−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−o−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
MX2013005414A (es) | 2010-11-16 | 2013-08-29 | Centre Nat Rech Scient | Derivados de monensina novedosos para el tratamiento y prevencion de infecciones por protozoarios. |
DK2643470T3 (da) | 2010-11-24 | 2016-05-17 | Univ Yale | Præparater og fremgangsmåder til behandling af iskæmisk skade med D-DT |
US20130296331A1 (en) | 2010-11-26 | 2013-11-07 | Technion Research And Development Foundation Ltd. | Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury |
WO2012074785A1 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
US8435993B2 (en) | 2010-12-07 | 2013-05-07 | Philadelphia Health And Education Corporation | Methods of inhibiting metastasis from cancer |
GB201020860D0 (en) | 2010-12-09 | 2011-01-26 | Univ Wolverhampton | Disulfiram formulation and uses thereof |
AU2011342284C1 (en) | 2010-12-15 | 2017-07-13 | Contravir Pharmaceuticals, Inc. | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
EP2654421B1 (en) | 2010-12-22 | 2016-10-19 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide as cgrp receptor antagonists |
WO2012093383A1 (en) | 2011-01-04 | 2012-07-12 | Radikal Therapeutics Inc. | Compositions and methods for treatment of sepsis and related conditions |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
RS61153B1 (sr) | 2011-01-07 | 2020-12-31 | Anji Pharma Us Llc | Ligand hemosenzornog receptora-osnovne terapije |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
WO2012122313A2 (en) | 2011-03-08 | 2012-09-13 | Access Pharmaceuticals, Inc. | Targeted nanocarrier systems for delivery of actives across biological membranes |
LT2683385T (lt) | 2011-03-10 | 2018-10-25 | Rigel Pharmaceuticals, Inc. | 2,4 pakeistieji pirimidindiaminai, skirti naudoti sergant diskoidine vilklige |
US8476221B2 (en) | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
CA2832422C (en) | 2011-04-06 | 2020-07-28 | Mcw Research Foundation, Inc. | Epoxyeicosatrienoic acid analogs and methods of making and using the same |
WO2012136221A1 (en) | 2011-04-08 | 2012-10-11 | Syddansk Universitet | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
US9480751B2 (en) | 2011-04-11 | 2016-11-01 | Yeda Research And Development Co. Ltd. | Albumin binding probes and drug conjugates thereof |
EP2697196A1 (en) | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US20140294957A1 (en) | 2011-04-18 | 2014-10-02 | Maxdelbruck-Centrum Fur Molekulare Medizin | Niclosamide for the treatment of cancer metastasis |
DK2705013T3 (da) | 2011-05-04 | 2016-07-18 | Balance Therapeutics Inc | Pentylenetetrazolderivater |
BR112013028890A2 (pt) | 2011-05-09 | 2017-01-31 | Univ Virginia Patent Foundation | composições e métodos para o tratamento de câncer |
EP2714029B1 (en) | 2011-05-27 | 2017-04-12 | Allergan, Inc. | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders |
WO2012163365A1 (en) | 2011-06-01 | 2012-12-06 | Concit Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
WO2012174243A1 (en) | 2011-06-17 | 2012-12-20 | Allergan, Inc. | D -serine for the treatment of visual system disorders |
CA2840396C (en) | 2011-06-27 | 2020-07-14 | Merial Limited | Amido-pyridyl ether compounds and compositions and their use against parasites |
WO2013003168A1 (en) | 2011-06-27 | 2013-01-03 | Merial Limited | Novel insect-repellent coumarin derivatives, syntheses, and methods of use |
WO2013005216A1 (en) | 2011-07-05 | 2013-01-10 | Radikal Therapeutics Inc. | Compositions and methods for treatment of renal ischemia-reperfusion injury |
JP6052685B2 (ja) | 2011-07-25 | 2016-12-27 | アラーガン、インコーポレイテッドAllergan,Incorporated | α2アドレナリン受容体の調節因子としてのN−(イミダゾリジン−2−イリデン)−ヘテロシクロペンタ[b]ピリジン誘導体 |
US8609658B2 (en) | 2011-07-27 | 2013-12-17 | Allergan, Inc. | N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof |
WO2013019169A1 (en) | 2011-08-01 | 2013-02-07 | Institute For Oneworld Health | Phosphate prodrugs |
WO2013036290A1 (en) | 2011-09-09 | 2013-03-14 | Yale University | Compositions and methods for assessing and treating inflammatory diseases and disorders |
EA027743B1 (ru) | 2011-09-09 | 2017-08-31 | Юниверсити Оф Вирджиния Пэтент Фаундейшн | Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости |
EP2758389B1 (en) | 2011-09-22 | 2017-06-07 | Merck Sharp & Dohme Corp. | Pyrazole carboxamides as janus kinase inhibitors |
WO2013052355A1 (en) | 2011-10-03 | 2013-04-11 | Merck Sharp & Dohme Corp. | Azaindoles as janus kinase inhibitors |
TWI619496B (zh) | 2011-11-03 | 2018-04-01 | 台灣微脂體股份有限公司 | 疏水性喜樹鹼衍生物之醫藥組合物 |
US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
ES2642715T3 (es) | 2011-11-17 | 2017-11-17 | Merial, Inc. | Composiciones que comprenden un aril pirazol y un imidazol sustituido, procedimientos y utilizaciones de las mismas |
US9713605B2 (en) | 2011-11-18 | 2017-07-25 | Simpson Biotech Co., Ltd. | Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death |
AU2012340806B2 (en) | 2011-11-21 | 2017-10-19 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
BR112014013150A2 (pt) | 2011-12-01 | 2017-06-13 | Chemocentryx Inc | benzimidazoles e benzopirazoles substituídas como antagonistas de ccr(4) |
AU2012345746B2 (en) | 2011-12-01 | 2016-12-08 | Chemocentryx, Inc. | Substituted anilines as CCR(4) antagonists |
EP3351546B1 (en) | 2011-12-02 | 2024-02-14 | Boehringer Ingelheim Vetmedica GmbH | Long-acting injectable moxidectin formulations |
US8993756B2 (en) | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
CA2860392C (en) | 2011-12-21 | 2016-08-30 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
ES2702237T3 (es) | 2011-12-21 | 2019-02-28 | Allergan Inc | Compuestos que actúan en receptores de prostaglandina múltiples que dan una respuesta antiinflamatoria general |
CA2862263C (en) | 2011-12-27 | 2016-09-06 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
US9090566B2 (en) | 2011-12-27 | 2015-07-28 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
CN110693868A (zh) | 2012-01-06 | 2020-01-17 | 埃尔舍利克斯治疗公司 | 双胍组合物和治疗代谢性病症的方法 |
KR102231554B1 (ko) | 2012-01-06 | 2021-03-23 | 앤지 파마 유에스 엘엘씨 | 대사 장애를 치료하는 조성물 및 방법 |
EP2814485A4 (en) | 2012-02-17 | 2015-08-26 | Merck Sharp & Dohme | DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
RU2627268C2 (ru) | 2012-02-29 | 2017-08-04 | Хемоцентрикс, Инк. | Аза-арил-1Н-пиразол-1-ил-сульфонамиды |
EP2828241B1 (en) | 2012-03-23 | 2018-09-12 | Mateon Therapeutics, Inc. | Compositions and methods for inhibition of cathepsins |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
JP2015519309A (ja) | 2012-04-16 | 2015-07-09 | カネック ファーマ インコーポレイテッド | Ptp−1bインヒビター前駆体としての縮合芳香族ホスホナート誘導体 |
EP2838520B1 (en) | 2012-04-17 | 2017-12-13 | University College Dublin National University Of Ireland, Dublin | Thromboxane receptor antagonists |
WO2013156861A2 (en) | 2012-04-17 | 2013-10-24 | University College Dublin, National University Of Ireland, Dublin | Methods and compounds for treating proliferative disorders and viral infections |
EP2838517B1 (en) | 2012-04-18 | 2017-10-18 | Contera Pharma APS | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
EP2846798B1 (en) | 2012-05-09 | 2018-04-04 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
EP2846799B1 (en) | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
US9227973B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyridine CGRP receptor antagonists |
WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
US20150368197A1 (en) | 2012-06-21 | 2015-12-24 | Radikal Therapeutics Ins. | Compositions and methods for treatment of inflammatory diseases of the lung |
EP2874622A4 (en) | 2012-07-23 | 2015-12-30 | Merck Sharp & Dohme | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS |
US20140024621A1 (en) | 2012-07-23 | 2014-01-23 | Ms Therapeutics Limited | Aminopyridine compounds and their uses |
US9555012B2 (en) | 2012-08-09 | 2017-01-31 | Dynamis Therapeutics, Inc. | Methods for maintaining or improving health, well-being and/or a physiological function in a subject |
US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
WO2014043257A1 (en) | 2012-09-12 | 2014-03-20 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
PL2722340T3 (pl) | 2012-10-19 | 2015-08-31 | Txp Pharma Gmbh | Analogi alfa- i gamma-msh |
US9938281B2 (en) | 2012-11-16 | 2018-04-10 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
LT2922845T (lt) | 2012-11-20 | 2018-09-10 | Merial, Inc. | Antihelmintiniai junginiai ir kompozicijos ir jų naudojimo būdai |
US9328116B2 (en) | 2012-12-07 | 2016-05-03 | Chemocentryx, Inc. | Diazole lactams |
CA2894715C (en) | 2012-12-21 | 2021-06-15 | Chemocentryx, Inc. | Diazole amides |
CA2898720A1 (en) | 2013-01-21 | 2014-07-24 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
EP2948150A1 (en) | 2013-01-25 | 2015-12-02 | Rigel Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory bowel diseases |
WO2014134774A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
AU2014224249B2 (en) | 2013-03-05 | 2017-10-05 | Salzman Group Pty. Ltd | Prodrugs of multifunctional nitroxide derivatives and uses thereof |
DK2968218T3 (da) | 2013-03-13 | 2021-09-20 | Neuroderm Ltd | Kombination til behandling af parkinsons sygdom |
SG11201507371RA (en) | 2013-03-14 | 2015-10-29 | Alkermes Pharma Ireland Ltd | Prodrugs of fumarates and their use in treating various deseases |
NZ711064A (en) | 2013-03-15 | 2019-06-28 | Verseon Corp | Pyridone-substituted pyrazolyl compounds as serine protease inhibitors |
CN110423221A (zh) | 2013-03-15 | 2019-11-08 | 维颂公司 | 作为凝血酶抑制剂的卤代吡唑 |
US9051294B2 (en) | 2013-04-30 | 2015-06-09 | Allergan, Inc. | Therapeutic agents |
WO2014194209A1 (en) | 2013-05-31 | 2014-12-04 | Allergan, Inc. | Substituted cyclopentenes as therapeutic agents |
ES2769893T3 (es) | 2013-07-02 | 2020-06-29 | Ecoplanet Env Llc | Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
WO2015026683A1 (en) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
TWI562787B (en) | 2013-10-23 | 2016-12-21 | Simpson Biotech Co Ltd | Uses of compounds and mixtures from antrodia cinnamomea mycelia |
US9315486B2 (en) | 2013-10-29 | 2016-04-19 | Allergan, Inc. | Therapeutic cyclopentanols, compositions thereof, and methods for use thereof |
PT3063144T (pt) | 2013-11-01 | 2021-10-28 | Boehringer Ingelheim Animal Health Usa Inc | Compostos de isoxazolina antiparasitários e pesticidas |
WO2015073344A1 (en) | 2013-11-14 | 2015-05-21 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
JP6563947B2 (ja) | 2013-12-02 | 2019-08-21 | ケモセントリックス,インコーポレイティド | Ccr6化合物 |
US9388153B2 (en) | 2013-12-20 | 2016-07-12 | Allergan, Inc. | Secondary amines as therapeutic agents |
EP3099667B1 (en) | 2014-01-27 | 2017-11-01 | Allergan, Inc. | Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation |
WO2015119848A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
ES2967693T3 (es) | 2014-03-13 | 2024-05-03 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
AU2015249540B2 (en) | 2014-04-22 | 2019-08-22 | Txp Pharma Gmbh | Peptide analogues with branched amino acid probe(s) |
WO2015162486A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues |
WO2015162483A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
US9394273B2 (en) | 2014-05-15 | 2016-07-19 | Allergan, Inc. | Therapeutic prostaglandin receptor agonists |
NZ726874A (en) | 2014-05-19 | 2018-03-23 | Merial Inc | Anthelmintic compounds |
WO2015179815A1 (en) | 2014-05-22 | 2015-11-26 | Allergan, Inc. | Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use |
KR101636758B1 (ko) * | 2014-05-30 | 2016-07-06 | 디씨에스이엔지 주식회사 | 회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치 |
BR112016028614A8 (pt) | 2014-06-06 | 2021-04-06 | Allergan Inc | novos agonistas de ep4, composição farmacêutica compreendendo os mesmos e seu uso |
US9908923B2 (en) | 2014-06-11 | 2018-03-06 | The Medical College Of Wisconsin, Inc. | Monomeric CXCL121 peptide and methods of use thereof |
WO2016009341A1 (en) | 2014-07-14 | 2016-01-21 | Radikal Therapeutics Inc. | Thioredoxin mimetic prodrugs and uses thereof |
GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
US10954240B2 (en) | 2014-09-03 | 2021-03-23 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2016044662A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
CA3224013A1 (en) | 2014-10-06 | 2016-04-14 | Chemocentryx, Inc. | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
EP3227292B1 (en) | 2014-12-02 | 2022-03-09 | Alterity Therapeutics Limited | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS |
WO2016092546A1 (en) | 2014-12-09 | 2016-06-16 | Ezekiel Golan | Binge behavior regulators |
BR112017017894A2 (pt) | 2015-02-20 | 2018-04-10 | Univ Leland Stanford Junior | composições de alérgenos misturados e métodos para usar as mesmas |
HUE060104T2 (hu) | 2015-02-27 | 2023-01-28 | Verseon Int Corporation | Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok |
JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および/またはリポジストロフィーの処置のための方法 |
JP6995627B2 (ja) | 2015-05-19 | 2022-02-04 | イエール ユニバーシティ | 病的石灰化状態を治療するための組成物およびそれを使用する方法 |
PL3298027T3 (pl) | 2015-05-20 | 2021-11-08 | Boehringer Ingelheim Animal Health USA Inc. | Przeciwrobacze związki depsipeptydów |
HUE050317T2 (hu) | 2015-05-20 | 2020-11-30 | Amgen Inc | APJ receptor triazol agonistái |
US11571462B2 (en) | 2015-06-03 | 2023-02-07 | The Medical College Of Wisconsin, Inc. | Engineered CCL20 locked dimer polypeptide |
US10738095B2 (en) | 2015-06-03 | 2020-08-11 | The Medical College Of Wisconsin, Inc. | Engineered CCL20 locked dimer polypeptide |
CN107921085B (zh) | 2015-06-15 | 2021-10-22 | 小利兰·斯坦福大学托管委员会 | 用于治疗衰老相关病症的方法和组合物 |
EP3865472A1 (en) | 2015-06-16 | 2021-08-18 | ATXA Therapeutics Limited | Thromboxane receptor antagonists |
AU2016278040B2 (en) | 2015-06-16 | 2019-07-04 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
WO2016205754A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
CN107708701A (zh) | 2015-06-30 | 2018-02-16 | 纽拉德有限公司 | 新颖呼吸控制调节化合物以及其制备和使用方法 |
WO2017007835A1 (en) | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for nanoemulsion vaccine formulations |
US11161801B2 (en) | 2015-08-10 | 2021-11-02 | Ramot At Tel-Aviv University Ltd. | Cationic pillararenes and uses thereof |
US11497813B2 (en) | 2015-11-02 | 2022-11-15 | Biovinc, Llc | Bortezomib conjugates and methods using same |
WO2017077528A2 (en) | 2015-11-02 | 2017-05-11 | Salzman Lovelace Investments, Ltd. | Methods and pharmaceutical compositions for treatment of lung inflammation |
WO2017079260A1 (en) | 2015-11-02 | 2017-05-11 | University Of Rochester | Phosphonate-chloroquine conjugates and methods using same |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Cxcr2抑制劑 |
EP4079322A1 (en) | 2015-11-20 | 2022-10-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
TWI791423B (zh) | 2016-01-14 | 2023-02-11 | 美商卡默森屈有限公司 | C3腎絲球病變之治療方法 |
CN108698991B (zh) | 2016-01-20 | 2022-08-23 | 凯莫森特里克斯股份有限公司 | 2-氧代吲哚化合物 |
AU2017216926A1 (en) | 2016-02-11 | 2018-08-02 | Eduard Berenshtein | Method and pharmaceutical composition for treatment of neurodegeneration |
UY37137A (es) | 2016-02-24 | 2017-09-29 | Merial Inc | Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos |
WO2017153977A1 (en) | 2016-03-08 | 2017-09-14 | Salzman Lovelace Investments, Ltd. | Solid formulations of resolvins and uses thereof |
CN109310686B (zh) | 2016-04-04 | 2022-06-21 | 凯莫森特里克斯股份有限公司 | 可溶性C5aR拮抗剂 |
WO2017177037A1 (en) | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
AU2017273871B2 (en) | 2016-06-03 | 2020-03-26 | Novacyte Therapeutics Company.,LTD | Polymer linkers and their uses |
US10036024B2 (en) | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
JP7185532B2 (ja) | 2016-06-27 | 2022-12-07 | ケモセントリックス,インコーポレイティド | 免疫調節化合物 |
JP7227896B2 (ja) | 2016-07-11 | 2023-02-22 | コンテラ ファーマ エー/エス | 朝の無動状態を治療するための拍動性薬物送達系 |
WO2018026764A1 (en) | 2016-08-01 | 2018-02-08 | University Of Rochester | Nanoparticles for controlled release of anti-biofilm agents and methods of use |
WO2018039508A1 (en) | 2016-08-25 | 2018-03-01 | Merial, Inc. | Method for reducing unwanted effects in parasiticidal treatments |
US10449230B2 (en) | 2016-10-06 | 2019-10-22 | The Regents Of The University Of California | Polymyxin derived cell penetrating scaffolds |
MX2019004266A (es) | 2016-10-14 | 2019-09-04 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos de vinil isoxazolina pesticidas y parasiticidas. |
CN110325542A (zh) | 2016-11-03 | 2019-10-11 | 劳伦斯·I·吴 | 克罗拉滨的前体药物 |
CA3040919A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma Corporation | Substituted pyridinone-containing tricyclic compounds, and methods using same |
US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
US11382949B2 (en) | 2016-11-16 | 2022-07-12 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic depsipeptide compounds |
WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
EP3541804A1 (en) | 2016-11-16 | 2019-09-25 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
MA46824A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj |
JP7013464B2 (ja) | 2016-11-23 | 2022-02-15 | ケモセントリックス, インコーポレイテッド | 巣状分節性糸球体硬化症を治療する方法 |
WO2018106928A1 (en) | 2016-12-08 | 2018-06-14 | Contravir Pharmaceuticals, Inc. | Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3 |
AU2017376398B2 (en) | 2016-12-14 | 2021-07-15 | Intervet International B.V. | Aminopyrazoles as selective janus kinase inhibitors |
MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのPPARγアゴニスト |
US20180296588A1 (en) | 2017-04-14 | 2018-10-18 | Contravir Pharmaceuticals, Inc. | Combination therapy for treating viral infections |
DE202017002464U1 (de) | 2017-05-09 | 2017-06-12 | St. Lotus Biotech Corp. | Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall |
EP3625248A4 (en) | 2017-05-18 | 2021-01-20 | The Rockefeller University | COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT OF DISEASES AND DISEASES ASSOCIATED WITH KCNJ5 MUTATIONS |
EP4092013A1 (en) | 2017-06-20 | 2022-11-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
JP7198269B2 (ja) | 2017-08-08 | 2022-12-28 | ケモセントリックス,インコーポレイティド | 大員環免疫調節剤 |
JP2020530850A (ja) | 2017-08-14 | 2020-10-29 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 殺有害生物および殺寄生生物ピラゾール−イソキサゾリン化合物 |
KR20200110300A (ko) | 2017-09-25 | 2020-09-23 | 케모센트릭스, 인크. | 케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법 |
US10758540B2 (en) | 2017-10-11 | 2020-09-01 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
EP3716985A1 (en) | 2017-11-27 | 2020-10-07 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Compounds, compositions, and methods for treating and/or preventing periodontal disease |
KR20200109316A (ko) | 2017-12-22 | 2020-09-22 | 케모센트릭스, 인크. | C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물 |
WO2019141957A1 (en) | 2018-01-19 | 2019-07-25 | Cado Biotechnology Ivs | N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof |
US11583545B2 (en) | 2018-02-08 | 2023-02-21 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof |
CA3091088A1 (en) | 2018-02-13 | 2019-08-22 | Beetlebung Pharma Ltd. | Cannabinoid derivatives and conjugates and uses thereof |
US10568874B2 (en) | 2018-02-22 | 2020-02-25 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
WO2019166877A1 (en) | 2018-03-02 | 2019-09-06 | Sixfold Bioscience Ltd. | Compositions for delivery of cargo to cells |
EP3773579A4 (en) | 2018-03-26 | 2022-03-09 | Clear Creek Bio, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE |
WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
US20190300526A1 (en) | 2018-04-02 | 2019-10-03 | Chemocentryx, Inc. | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
EP3552605A1 (en) | 2018-04-11 | 2019-10-16 | Univerzita Palackého V Olomouchi | Mcoppb for use as medicament |
US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
EA202092691A1 (ru) | 2018-05-29 | 2021-04-21 | Церси Терапьютикс, Инк. | Соединения для устранения боли, композиции, содержащие их, и способы их применения |
WO2019236984A1 (en) | 2018-06-08 | 2019-12-12 | The Medical College Of Wisconsin, Inc. | Methods of treating vascular leakage using cxcl12 peptides |
US20220048903A1 (en) | 2018-07-09 | 2022-02-17 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic Heterocyclic Compounds |
JP2021536467A (ja) | 2018-09-06 | 2021-12-27 | インノファーマスクリーン インコーポレイテッド | 喘息またはパーキンソン病の処置のための方法および組成物 |
JP7464591B2 (ja) | 2018-10-10 | 2024-04-09 | ブイティーブイ・セラピューティクス・エルエルシー | [3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物 |
EP3866794A4 (en) | 2018-10-17 | 2022-07-20 | Imbria Pharmaceuticals, Inc. | METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE COMPOUNDS |
EP3873471A4 (en) | 2018-10-31 | 2022-06-15 | Merck Sharp & Dohme Corp. | N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES |
WO2020092845A1 (en) | 2018-11-01 | 2020-05-07 | Rigel Pharmaceuticals, Inc. | Method and composition embodiments for treating acute myeloid leukemia |
US11773066B2 (en) | 2018-11-20 | 2023-10-03 | Boehringer Ingelheim Animal Health USA Inc. | Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof |
TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
WO2020159565A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent |
US20200246317A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent |
CN113825543A (zh) | 2019-03-19 | 2021-12-21 | 勃林格殷格翰动物保健美国公司 | 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物 |
US11471508B2 (en) | 2019-05-09 | 2022-10-18 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of diabetic peripheral neuropathy |
WO2020243612A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
US20220259188A1 (en) | 2019-06-06 | 2022-08-18 | Merck Sharp & Dohme Corp. | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
EP3997060A4 (en) | 2019-07-08 | 2023-07-19 | Rezolute, Inc. | METHODS FOR PREPARING PLASMA KALLIKREIN INHIBITORS |
CA3145303A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
MX2022001596A (es) | 2019-08-08 | 2022-03-11 | Rigel Pharmaceuticals Inc | Compuestos y metodos para tratar sindrome de liberacion de citocinas. |
CN114286679A (zh) | 2019-08-14 | 2022-04-05 | 里格尔药品股份有限公司 | 阻断或改善细胞因子释放综合征的方法 |
US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
JP2023519890A (ja) | 2020-03-27 | 2023-05-15 | アクラリス セラピューティクス,インコーポレイテッド | 免疫状態の処置のためのmk2経路阻害剤の経口組成物 |
TW202203916A (zh) | 2020-03-31 | 2022-02-01 | 美商卡默森屈有限公司 | 使用ccr9抑制劑及抗il—23阻斷抗體治療發炎性腸道疾病的組成物及方法 |
EP4139458A1 (en) | 2020-04-23 | 2023-03-01 | AZTherapies, Inc. | Cellular ablation of hla-class i mhc |
CA3176025A1 (en) | 2020-04-24 | 2021-10-28 | Nuvamid Sa | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
EP3901160A1 (en) | 2020-04-25 | 2021-10-27 | Nuvamid SA | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
JP2023523345A (ja) | 2020-04-27 | 2023-06-02 | シックスフォールド バイオサイエンス リミテッド | モジュール官能基を有する核酸ナノ粒子を含有する組成物 |
KR20230005304A (ko) | 2020-04-30 | 2023-01-09 | 아네트 엠. 토비아 | 시토카인 폭풍을 치료하기 위한 조성물 및 방법 |
EP4157877A2 (en) | 2020-05-28 | 2023-04-05 | AZTherapies, Inc. | Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases |
PE20231205A1 (es) | 2020-05-29 | 2023-08-17 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos como anthelminticos |
US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
BR112023000168A2 (pt) | 2020-07-07 | 2023-01-31 | Atxa Therapeutics Ltd | Formulações de antagonistas do receptor de tromboxano |
WO2022013430A1 (en) | 2020-07-17 | 2022-01-20 | Université De Bretagne Occidentale | New glycolipids and use thereof as sk3 ion channel modulators |
WO2022029275A1 (en) | 2020-08-06 | 2022-02-10 | Nuvamid Sa | Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19 |
WO2022029287A1 (en) | 2020-08-07 | 2022-02-10 | Nuvamid Sa | Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity |
CN116390938A (zh) | 2020-08-12 | 2023-07-04 | Txp制药股份有限公司 | 毒蜥外泌肽-4类似物 |
EP4228675A1 (en) | 2020-10-13 | 2023-08-23 | Betavive Ltd. | Method and compounds for treating diabetes and associated metabolic diseases |
GB202017255D0 (en) | 2020-10-30 | 2020-12-16 | Queens Univ Of Belfast | Immunomodulatory agent |
GB202017251D0 (en) | 2020-10-30 | 2020-12-16 | Queens Univ Of Belfast | Neurodegenerative treatment |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11969422B2 (en) | 2020-12-10 | 2024-04-30 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine |
US11730733B2 (en) | 2020-12-10 | 2023-08-22 | Imbria Pharmaceuticals, Inc. | Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine |
US11793807B2 (en) | 2020-12-10 | 2023-10-24 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine |
WO2022129536A1 (en) | 2020-12-18 | 2022-06-23 | Nuvamid Sa | Nicotinamide mononucleotide derivatives and use thereof in the stimulation of the expression of fetal hemoglobin |
AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
CN116940350A (zh) | 2021-02-08 | 2023-10-24 | 博施健康爱尔兰有限公司 | 预防、治疗或改善溃疡性结肠炎的阿米莫德 |
WO2022184685A1 (en) | 2021-03-01 | 2022-09-09 | Nuvamid Sa | Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19 |
EP4070799A1 (en) | 2021-04-08 | 2022-10-12 | Nuvamid SA | Compositions for the improvement of sport performance |
EP4079311A1 (en) | 2021-04-20 | 2022-10-26 | Nuvamid SA | Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism |
EP4079310A1 (en) | 2021-04-20 | 2022-10-26 | Nuvamid SA | Nmn and derivatives for its use in the treatment of alpha-synucleinopathies |
US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
EP4346763A1 (en) | 2021-05-31 | 2024-04-10 | Cannabotech Ltd. | Compositions comprising a cannabinoid and uses thereof |
CA3222984A1 (en) | 2021-06-17 | 2022-12-22 | Laurent GARCON | Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction |
WO2022263676A1 (en) | 2021-06-18 | 2022-12-22 | University Of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
WO2023012182A1 (en) | 2021-08-02 | 2023-02-09 | Nuvamid Sa | Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome |
WO2023062545A1 (en) | 2021-10-12 | 2023-04-20 | Betavive Ltd. | Peptides and fragments for treating diabetes and associated metabolic diseases |
US20240116945A1 (en) | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
WO2024052895A1 (en) | 2022-09-06 | 2024-03-14 | Hadasit Medical Research Services And Development Ltd | Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders |
WO2024091437A1 (en) | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2211485A (en) * | 1940-08-13 | Effervescent acetyl salicylic acid | ||
US536155A (en) * | 1895-03-19 | Pill or tablet | ||
US2312381A (en) * | 1940-10-24 | 1943-03-02 | Frank J Bickenheuser | Medicinal tablet |
US3062715A (en) * | 1953-11-18 | 1962-11-06 | George S Pfaus | Vaginal tablet |
GB917456A (en) * | 1958-10-30 | 1963-02-06 | Casco Lab Inc | Suppository composition and preparation thereof |
US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
US3136692A (en) * | 1961-06-30 | 1964-06-09 | Strong Cobb Arner Inc | Effervescent composition containing polyvinylpyrrolidone |
GB1093286A (en) * | 1965-02-15 | 1967-11-29 | Biorex Laboratories Ltd | Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents |
FR5391M (da) * | 1965-11-04 | 1967-10-23 | ||
GB1123316A (en) * | 1966-12-09 | 1968-08-14 | Wynlit Pharmaceuticals Trust R | Improvements in suppositories |
US3495001A (en) * | 1968-05-27 | 1970-02-10 | Miles Lab | Effervescent compositions of acetylsalicylic acid |
US3887700A (en) * | 1969-11-28 | 1975-06-03 | Aspro Nicholas Ltd | Analgesic formulations |
US3676549A (en) * | 1970-09-30 | 1972-07-11 | Alza Corp | Administration of alkali metal salts of salicylamide |
US3764668A (en) * | 1970-09-30 | 1973-10-09 | Interx Research Corp | Compositions of salts of salicylamide |
GB1359614A (en) * | 1971-04-06 | 1974-07-10 | Dev Et De Rech Soc Fr De | Method for the manufacture of effervescent tablets |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4036228A (en) * | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
US4160452A (en) * | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
-
1980
- 1980-04-25 US US06/143,644 patent/US4265874A/en not_active Expired - Lifetime
-
1981
- 1981-02-12 AT AT81300572T patent/ATE9267T1/de not_active IP Right Cessation
- 1981-02-12 EP EP81300572A patent/EP0040899B1/en not_active Expired
- 1981-02-12 DE DE8181300572T patent/DE3165901D1/de not_active Expired
- 1981-03-19 NZ NZ196561A patent/NZ196561A/xx unknown
- 1981-04-02 PT PT72796A patent/PT72796B/pt not_active IP Right Cessation
- 1981-04-03 IE IE765/81A patent/IE51216B1/en not_active IP Right Cessation
- 1981-04-10 GR GR64674A patent/GR73519B/el unknown
- 1981-04-22 ES ES1981267593U patent/ES267593Y/es not_active Expired
- 1981-04-24 JP JP6154181A patent/JPS56167617A/ja active Granted
- 1981-04-24 DK DK184681A patent/DK152482C/da active
-
1982
- 1982-03-25 ES ES510822A patent/ES510822A0/es active Granted
Also Published As
Publication number | Publication date |
---|---|
DK184681A (da) | 1981-10-26 |
DK152482C (da) | 1988-08-01 |
EP0040899A2 (en) | 1981-12-02 |
DE3165901D1 (en) | 1984-10-18 |
ES8307092A1 (es) | 1983-06-16 |
ES267593U (es) | 1983-05-16 |
ATE9267T1 (de) | 1984-09-15 |
US4265874A (en) | 1981-05-05 |
JPH044293B2 (da) | 1992-01-27 |
EP0040899B1 (en) | 1984-09-12 |
EP0040899A3 (en) | 1982-08-11 |
PT72796A (fr) | 1981-05-01 |
JPS56167617A (en) | 1981-12-23 |
ES267593Y (es) | 1983-11-16 |
PT72796B (fr) | 1982-03-30 |
IE51216B1 (en) | 1986-11-12 |
ES510822A0 (es) | 1983-06-16 |
NZ196561A (en) | 1983-05-10 |
IE810765L (en) | 1981-10-25 |
GR73519B (da) | 1984-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK152482B (da) | Osmotisk drevet organ til reguleret indgift af et aktivt middel til et vandigt, surt vaeskemiljoe | |
US4344929A (en) | Method of delivering drug with aid of effervescent activity generated in environment of use | |
JPS596843B2 (ja) | 薬剤供給体の製造法 | |
US4627850A (en) | Osmotic capsule | |
CA1047874A (en) | Osmotically driven dispenser and process for making same | |
CA1265966A (en) | Rate controlled dispenser for administering beneficial agent | |
US4290426A (en) | Dispenser for dispensing beneficial agent | |
CA2032923C (en) | Long-term delivery device including loading dose | |
NL192720C (nl) | Osmotische inrichting voor de afgifte van een voor een gebruiksomgeving voordelig middel. | |
KR100246157B1 (ko) | 약물 전달의 지연 활성화 삼투 장치 | |
US4235236A (en) | Device for dispensing drug by combined diffusional and osmotic operations | |
KR950003920B1 (ko) | 투약기내의 자체 구동력에 의해 투약기 밖으로 이동될 수 있는 약제수용된 담체를 포함하는 투약기 | |
DE3634864C2 (de) | Abgabevorrichtung zum Freisetzen einer wärmeempfindlichen Wirkstoffzubereitung | |
DE3626362C2 (de) | Abgabevorrichtung zur Freisetzung eines Wirkstoffes an Wiederkäuer | |
EP0250083B1 (en) | Dosage form with means for governing rate of gas formation | |
JPH0428242B2 (da) | ||
NL8401470A (nl) | Osmotische inrichting met tweevoudige thermodynamische activiteit. | |
JPS61249916A (ja) | 不活性なコア部を有する浸透圧利用薬剤投与具 | |
FR2580499A1 (fr) | Dispositif osmotique d'apport ayant un passage automatiquement ferme | |
JPS61185272A (ja) | 脂質浸透ポンプ | |
JPH0623090B2 (ja) | 半透過性部と腸溶性部から形成された外壁を有する薬剤デイスペンサ− | |
US4610686A (en) | Controlled delivery of haloperidol by an osmotic delivery system | |
JPS6210205B2 (da) | ||
US4484921A (en) | Theophylline therapy utilizing osmotic delivery | |
US4439195A (en) | Theophylline therapy |